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  Abstract 
Studies on the Nucleocytoplasmic Transport of the E7 Oncoprotein of 
High-Risk HPV Type 16 
Jeremy Eberhard 
Thesis Advisor: Prof. Junona Moroianu, Ph.D 
 
Human papillomaviruses (HPVs) have been estimated to be the most common 
sexually transmitted infection in the United States. In addition to condyloma 
accuminata, infection of the squamos basal epithelium by high-risk HPVs, 
notably type 16 (HPV16), has been shown to be the primary etiological agent in 
the majority of cervical carcinomas.  
 
The E7 major transforming protein of HPV16, along with E6, has been linked to 
tumorigenesis and malignancy. While the E7 protein itself possesses no 
enzymatic activity, its ability to bind a number of nuclear and cytoplasmic targets 
subverts a variety of cellular regulatory complexes and facilitates viral replication. 
 
Previous studies in the Moroianu Lab have shown the HPV16 E7 oncoprotein to 
translocate across the nuclear pore complex (NPC) in a facilitated manner 
dependent on a non-canonical, c-terminal, nuclear localization signal (cNLS) for 
import, and a consensus leucine-rich nuclear export sequence (NES) for export 
(28). While the leucine-rich NES has been characterized, a full examination of 
the cNLS has yet to be performed.  
	  Here we present evidence that the karyopherin independent nuclear import 
mediated by the cNLS of 16E7 is dependent on its c-terminal Zn binding domain. 
Furthermore, we demonstrate that nuclear import is mediated by the direct 
interaction of a small patch of hydrophobic residues, 65LRLCV69, with the FG 
domain of the central FG-nucleoporin Nup62. 
 
In addition, we examined a potential regulatory mechanism of 16E7 
nucleocytoplasmic translocation. Previous work has shown that a serine 
conserved in the high-risk HPVs at position 71 is phosphorylated by an unknown 
kinase. Here we present evidence that while phosphorylation of S71 is not 
required for either 16E7 nuclear localization or nuclear export in HeLa cells, 
mimicking phosphorylation of the S71 residue results in a statistically significant 
shift in the distribution of localization phenotypes of the resultant cell population 
toward a larger percentage exhibiting more nuclear localization. These data 
suggest that nucleocytoplasmic transport of 16E7 is, at least in part, a regulated 
process. 
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CHAPTER 1 
Introduction 
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Human Papillomaviruses  
 
The large and diverse papillomaviridae family, first identified and described in 
cottontail rabbits, is now thought to occur in many species of mammals and birds 
(12, 65). Similar to other members of the family, the human papillomaviruses 
(HPVs) are small, non-enveloped, double-stranded DNA tumor viruses with a 55-
nm icosahedral capsid that exhibit a marked tropism for squamous basal 
epithelial cells (7, 12, 13, 32, 48). To date more than 200 genetically distinct 
HPVs have been identified in the Alpha, Beta, Gamma, Mu, and Nu genera with 
approximately 90% of HPVs represented in either the Alpha or Beta genera (12, 
13, 32, 48).   
 
Infections with Beta papillomaviruses, notably HPV5 and HPV8, are typically 
asymptomatic, however, infection in either immune-compromised or individuals 
suffering from the rare genetic skin disease epidermodysplasia verruciformis 
(EV) can lead to a variety of non-melanoma skin cancers, and in fact, EV-
associated skin cancer was the first directly linked to HPV infection (42, 57, 61, 
62, 80). The largest individual group of HPVs however are the Alpha 
papillomaviruses, and consists of both cutaneous viruses known to cause 
common warts, as well as the approximately 40 types known to infect the cervical 
epithelium (12, 13, 45). These Alpha HPVs may be further sub-divided into high 
and low-risk groups, dependent upon the frequency with which they have been 
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linked to the malignant progression of their resultant lesions (12, 13, 32, 45, 48, 
56, 64).  
 
Although they were the first to be linked to HPV associated tumors, most of the 
HPVs that infect the squamous epithelium of the genital tract can be classified as 
low risk, and are only very rarely found to lead to cancers even if left untreated 
(13, 15, 17, 18, 32, 48, 64, 74). Infection with low risk HPVs is associated 
primarily with condyloma accuminata (genital warts), about 90% of which are 
caused specifically by HPV6 and HPV11 (13, 32, 48, 64). Conversely, 15 of the 
sexual transmitted genital HPVs can be classified as high risk, notably HPV16, 
HPV18, HPV31, HPV33 and HPV45, which may result in squamous 
intraepithelial lesions capable of progressing to invasive carcinomas (13, 15, 32, 
45, 48). Recent work has suggested that these differences observed between 
high risk and low risk types of HPV are a result of two distinct evolutionary 
strategies to balance viral persistence versus per-contract transmission 
probability, and that the type favored will be based upon the sexual behaviors in 
a host population (56). 
 
While limited variety exists between subtypes and genera, the majority of 
different HPV genomes typically contain about 8,000 base pairs, consisting of 
eight, or rarely, nine, open reading frames all transcribed from a single DNA 
strand, the entirety of which is typically associated with cellular histones to form 
structures resembling chromatin (12, 13, 32, 40, 48). The genome can be broadly 
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divided into three major sections; 1) an approximately 4-kb early (E) section that 
encodes for the six non-structural viral proteins, 2) an approximately 3-kb late (L) 
region that encodes for the two structural viral proteins, and 3) a roughly 1-kb 
non-coding regulatory region (13, 32, 42, 48). Each gene is designated first as 
either Early or Late, then further identified numerically according to size, with the 
largest open reading frames numbered first, and the smallest last (13, 32, 48). All 
eight open reading frames are expressed under the control of two major 
promoters; one primarily active in the early stage of the viral life cycle which 
initiates transcription upstream of the E6 open reading frame, the other in the late 
stage of the viral life cycle which initiates transcription at a variety of 
heterogeneous sites shown to cluster around nucleotide 742 in HPV-31 and 670 
in HPV-16 (13, 32). The eight open reading frames are transcribed to form 
several different polycistronic mRNAs, each containing three or more open 
reading frames (13, 32). Gene expression from these polycistronic mRNAs is 
regulated, at least in part, via alternative splicing and differential polyadenylation 
site usage (13, 32).  
 
The two late stage proteins, L1 and L2, serve to make up the viral capsid shell, 
with 360 L1 molecules assembling into 72 pentavalent capsomeres held together 
via intermolecular disulfide bonds between the C-terminal arms of the L1 proteins. 
It is estimated that there are 72 molecules of L2 minor capsid protein, with each 
L2 located at the center of the pentamer (5, 10, 13, 26, 33, 43, 44, 51-53). The 
E1 and E2 proteins are thought to be critical for early viral replication and for the 
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establishment of a stable viral episome in the host cells (13, 32, 48). While the 
E1 protein has been shown to act primarily as a helicase with ATPase activity, 
E2 has been implicated in multiple roles, including: 1) acting as a DNA binding 
transcription factor, 2) recruiting E1 helicase, 3) viral genome segregation, and, 
most importantly, 4) regulating the expression of the E6 and E7 proteins (13, 23, 
27, 32, 48). The role of the E4 protein has yet to be fully established, however, it 
has been implicated as playing a role in the late stages of viral infection and is 
known to antagonize the effects of E7 by arresting the cell in G2 phase (13, 32). 
The E4 protein has also been reported to facilitate viral egress by disrupting the 
keratin networks of the host cells (13, 32). The E5 protein, a transmembrane 
protein that resides primarily in the endoplasmic reticulum and Golgi apparatus, 
is a weak transforming protein capable of augmenting the transforming ability of 
E6 and E7 and contribute to tumor progression (13, 32, 45, 79). The major 
contribution of E5 to cellular transformation is thought to occur primarily through 
modulating transit of signaling proteins, notably epidermal growth factor, through 
the endoplasmic reticulum leading to enhanced cellular proliferation (6, 22, 30). 
In addition, E5 has also been shown to down regulate and reduce levels of major 
histocompatibility complex class I on the cell surface leading to a reduction in 
recognition by CD8 T cells that may aid in the preventing clearance of HPV 
infected cells by the immune response (3, 8, 45). The E6 protein is, along with 
the major transforming protein E7, and to a lesser extent E5, responsible for the 
transformation of primary human keratinocytes (13, 22, 29, 32, 40, 44, 48, 79). 
E6 has been shown to interact with a wide variety of different cellular targets and 
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perform roles both in the nucleus and in the cytoplasm (13, 22, 29, 32, 40, 44, 45, 
48, 79). These roles include; formation of a trimeric complex with p53 and E6AP 
that leads to the degradation of p53, activation of telomerase, enhancement of 
foreign DNA integration and mutagenicity, chromosomal instability, immune 
avoidance, and cellular immortalization (13, 22, 29, 32, 40, 44, 48, 79). The 
activity of the major transforming E7 oncoprotein will be discussed in depth in 
subsequent sections. 
 
Initial infection with papillomaviruses occurs through microtraumas in the 
epithelium allowing the virus access to the basal epithelial layer (13, 32, 45, 48). 
While a specific cell surface receptor(s) for HPV has yet to be identified, integrin 
α4β6 has been implicated along with heparan sulfate in mediating initial binding 
and viral uptake (13, 48). Previous studies have reported viral entry to be 
dependent on either clathrin or caveolin mediated endocytosis, however, more 
recent work has instead suggested that tetraspanin-enriched microdomains 
(TEMs) may play the critical role in viral uptake, and that clathrin or caveolin 
mediated endocytosis may be unnecessary for viral entry into the cell (11, 21, 69). 
Following entry, the virion particles disassemble in the late endosomes and the 
viral DNA is then transferred to the nucleus via the L2 minor capsid protein (5, 10, 
13, 26).  As soon as 12 hours post infection, initial viral transcripts can be 
detected, and it is thought that the first viral proteins to be expressed are the E1 
and E2 replication factors (13). During early stages of infection, E1 and E2 work 
to maintain a stable viral episome consisting of somewhere between 20 and 100 
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copies of the viral genome in each infected basal epithelial cell (13, 32, 45). In 
the basal cells, the viral DNA appears to be replicated concurrent with cellular S-
phase and viral genomes are partitioned to each of the daughter cells equally, 
largely via the activity of E2 (13). As the basal epithelial cells differentiate and 
proceed from the stratum basale, through the stratum granulosum, and into the 
suprabasal layer, uninfected epithelial cells would normally exit the cell cycle and 
begin terminal differentiation (13, 32, 48). However, in infected cells, E7, and to a 
lesser extent E6 and E5, act to retain cell cycle progression and prevent terminal 
differentiation (13, 22, 32, 45, 48). As the infected cell progresses through the 
suprabasal layer, the virus begins to replicate in high copy number and shifts to 
production of the late stage genes, with L2 expression preceding L1 (13, 32, 48). 
The two late stage proteins then assemble spontaneously with the aid of E2 into 
icosahedral capsids and the mature viruses are shed into the environment as 
cargo within sloughed epithelial squame (13, 32, 45, 48). 
 
Human Papillomaviruses are estimated to be the most common sexually 
transmitted infection in the United States (14, 64, 70). Lifetime infection rates are 
estimated to be 50% for the overall population, reaching 80% for women by age 
50 (70). Active infection rates within the population are estimated to be around 
26.8% for women between the ages of 14 and 59 years, with the highest rate of 
infection, 44.8%, occurring in women between the ages of 20 and 24 years (14). 
The overall prevalence of high and low risk HPV has been estimated to be 15.2% 
and 17.8%, respectively (14). Striking, though nearly 99% of cervical cancers and 
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20% of oropharynx cancers are positive for HPV DNA, with HPV16 found in 
nearly 63% and HPV18 found in 10-14% of the cervical cancers, HPV16 was 
found in only 1.5% and HPV18 in only 0.8% of all women between the ages of 14 
and 59 years (13, 14, 32, 48). Although the majority of women have been shown 
to clear infection within 18 months, it is the low-percentage persistent high-risk 
HPV infections that are the single greatest risk for developing genital cancers (13, 
32, 48, 64, 70, 79). Cervical cancer is the second most common cancer, and the 
fifth leading cause of death in women worldwide, with approximately 470,000 
new cases and 233,000 deaths reported yearly with a median age of onset of 52 
years (32, 64, 70). Although in the United States only about 10,000 of the 
estimated 4.6 million new cases of HPV progress to cervical cancer, and due to 
wide use of the Pap smear diagnostic, 80% of cervical cancer fatalities occur in 
the developing world, HPV remains a public health concern with an estimated 
$2.9 billon direct medical cost and 5,000 deaths reported annually (32, 70). 
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The Human Papillomavirus E7 Major Transforming Protein  
 
All small acidic phosphoproteins of approximately 100 amino acids, the HPV E7 
proteins share both structural and functional similarities to the adenovirus E1A 
protein and the SV40 large tumor antigen (2, 4, 28, 40, 41, 45, 49, 59). The E7 
protein was the first oncogene of the high-risk HPVs to be discovered and, along 
with E6, is consistently expressed in the tumors of virtually all HPV associated 
carcinomas (2, 4, 28, 40, 41, 45, 49, 59). Together, E6 and E7 work 
cooperatively to induce cellular immortalization and transformation, and 
additionally are required for the maintenance of the transformed state (2, 4, 28, 
40, 41, 45, 49, 59). Whereas the ability of the E7 protein to promote 
transformation and immortalization is strongly correlated to the low-risk/high-risk 
HPV classification, studies in transgenic mice have suggested that the E7 protein 
serves primarily to promote the formation of benign tumors, and that it is E6 
expression that is linked to the progression of the tumors to malignancy (28, 41, 
67).  
 
Of particular note, E7 itself possesses no intrinsic enzymatic or DNA binding 
activity; instead, the E7 protein carries out its biological activities through its 
ability to associate with and subvert a variety of cellular regulatory complexes 
involved in several key host cell signal transduction networks (2, 4, 28, 40, 41, 45, 
49, 59). To date, the E7 protein has been shown to bind a wide variety of 
different cellular proteins, including: cell cycle regulators, transcription factors and 
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cofactors, chromatin remodeling enzymes, metabolic enzymes, as well as the 
proteasome (4, 24, 39, 41, 49, 59). To date the best-characterized interactions of 
E7 remains its interaction with the retinoblastoma protein (pRB) and related 
pocket proteins p107 and p130 (4, 40, 41, 45, 49, 59). Binding of the E7 protein 
with pRB facilitates disruption of pRB binding and regulation of the E2F family of 
transcription factors and their responsive genes and, for high risk HPVs, 
additionally targets pRB for proteasomal degradation (4, 41, 49). In addition to 
pRB binding, E7 has also been shown to interact with cyclin A and E, cyclin 
dependent kinase (cdk) 2, and, via p107 mediated interactions, the cdk inhibitors 
p27 and p21 (4, 40, 41, 45, 49). In total, these interactions induce 
hyperproliferation via deregulation of G1/S phase entry and progression which 
allow the virus access to the host cell replication machinery in normally quiescent 
cells that otherwise could not support viral replication (4, 40, 41, 45, 49). 
Additionally, up-regulation of cdk2 by E7 can interfere with ordered centrosome 
synthesis and can result in multipolar mitoses and aneuploidy, ultimately 
contributing to the malignant progression of cervical tumors (41, 49). In addition 
to nuclear targets, E7 has also been shown to bind cytoplasmic proteins, notably 
with the microtubule-associated N-end ubiquitin ligase p600 that is thought to 
prevent anoikis (apoptosis in response to deregulated S-phase entry), as well as 
to the nuclear mitotic apparatus protein (24, 40, 41, 45, 49, 54). Together with the 
previously described functions, current research suggests important roles for E7 
in both the nucleus and the cytoplasm (2, 4, 24, 28, 40, 41, 45, 49, 67).   
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Structurally, the E7 proteins consist of three biochemically distinct domains (2, 4, 
28, 40, 41, 49). Both NMR and X-ray crystal structures have been solved for E7, 
and the three-dimensional structure has been shown to organize into a tightly 
packed C-terminal zinc-binding fold and an unfolded amino terminus (Figure A) 
(40, 41). Pursuant to the focus of this study, the following specifics regarding 
structure and biochemistry will be in the context of the high-risk HPV16 E7 
protein. The two amino terminus conserved regions (CR) CR1 (aa1-15) and CR2 
(aa16-37) of 16E7 possess both significant sequence similarity to a portion of 
CR1 and the entirety of CR2 of adenovirus E1A and related sequences of SV40 
large tumor antigen, as well as functional similarity, having been shown to 
significantly contribute to the transforming ability of 16E7 (2, 4, 28, 41, 49). The 
CR2 domain contains both the Leu-X-Cys-X-Glu (LXCXE) pRB binding motif as 
well as a consensus casein kinase II (CKII) phosphorylation site (28, 41). The C-
terminal CR3 domain (aa38-98) contains a zinc-binding domain with two Cys-X-
X-Cys motifs (28, 41, 49). In addition to the zinc-binding domain, the CR3 domain 
has also been shown to have a high risk HPV conserved serine 71 residue that is 
differentially phosphorylated throughout the cell cycle (28, 35, 41, 49). Although 
neither the kinase nor its mechanism has yet been elucidated, phosphorylation of 
this serine residue has been hypothesized as a means of regulating E7 activity 
throughout the cell cycle (28, 35, 41, 49). 
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Figure A:	  Schematic representation of the HPV E7 oncoprotein.  
The unstructured amino terminal 37 amino acid residues of HPV16 E7 have sequence similarity 
to a portion of CR1 (green) and the entire CR2 (red) of Ad E1A, with specific identical and 
chemically similar amino acid residues indicated by red and blue boxes, respectively. CR1 
sequences are required for cellular transformation and pRB degradation but do not directly 
contribute to pRB binding. The core pRB binding site (LXCXE), also required for transformation, 
is located within CR2, adjacent to a casein kinase II consensus phosphorylation site (CKII). The 
carboxyl terminal E7 domain shown here is from HPV45 E7 as determined by X-ray 
crystallography (55). This portion of the E7 sequence has a compact β1β2α1β3α2 topology that 
represents a unique zinc-binding fold. The cysteine residues involved in zinc binding are indicated 
in yellow. They are arranged as two Cys-X-X-Cys motifs separated by 29 amino acid residues(41).  
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Nuclear Import and Export of Macromolecules 
 
The physical separation of nuclear DNA synthesis and cytoplasmic protein 
synthesis in eukaryotic cells necessitates selective and regulated transport 
across the double lipid bilayer of the nuclear envelope in order to carry out critical 
biological functions. This transport of protein and RNA cargos across the nuclear 
envelope occurs through large macromolecular structures called Nuclear Pore 
Complexes (NPC) (19, 46, 47, 58, 63, 68, 72). The NPC can grossly be 
described as consisting of three biochemically distinct domains organized into a 
nucleoplasmic ring and nuclear basket, a central core, and a cytoplasmic ring 
with associated filaments (19, 46, 47, 63, 68, 72). Structurally the NPC is 
comprised of about 30 different proteins called nucleoporins (Nups) present in 
multiple copies organized in an eight-fold symmetry (46, 47, 58, 63, 68, 72). The 
Nups themselves can be divided into four classes: 1) structural Nups, 
responsible for the overall shape and form of the NPC, 2) pore membrane 
proteins (Poms), which anchor the NPC in the nuclear envelope, 3) FG-Nups, 
with discrete domains of either FG, GLFG, or FxFG repeats that help facilitate 
macromolecular transport across the NPC, and 4) a newly emerging class of 
WD/Seven-blade-propeller motif Nups found to play a role in mRNA export (46, 
47, 58, 63, 68, 72). Transport across the NPC may be either a passive or an 
active process. The pore of the NPC can open to a maximum of 25 nm and allow 
cargos up to approximately 40 kDa that do not interact with the FG-Nups to 
passively diffuse; conversely, cargos in excess of 40 kD, or those that interact 
	   14	  
with FG-Nups, require the active participation of a transport receptor to facilitate 
their translocation across the NPC (19, 46, 47, 58, 63, 68, 72). The largest and 
best characterized group of these transport receptors is comprised of the 
structurally related karyopherin-β (Kapβ, importin/exportin) superfamily, which 
either directly, or indirectly via an adaptor protein, specifically recognize transport 
signals on the cargo molecule for either nuclear import or nuclear export (19, 46, 
47, 58, 63, 68, 72). 
 
Nuclear transport of proteins unable to diffuse, yet still able to enter the nucleus, 
is in most cases due to the presence of either a nuclear localization signal (NLS) 
for import, or a nuclear export signal (NES) on the cargo molecule (19, 46, 47, 58, 
68). In general, nuclear import/export of an NLS/NES containing cargo is 
facilitated in one of two ways.  Signal containing cargos can either be bound by 
karyopherins directly, or, alternatively, via an adaptor in one compartment, and 
are then translocated through the NPC and released in the other compartment 
(19, 46, 47, 58, 68). Following translocation, both the receptor and any adaptor 
are recycled back to their original compartment (19, 46, 47, 58, 68). The first 
identified NLS, the ‘classical NLS,’ consists of either a short 3-5 basic amino acid 
sequence (monopartite NLS) or a longer bipartite signal with an additional 2 
basic amino acids upstream of a simple basic sequence (46, 47, 58, 68). In 
proteins with either classical NLS, karyopherin α binds the NLS of the cargo 
protein and acts as an adaptor between the cargo and karyopherin β1, which in 
turn will mediate NPC translocation through interactions with FG-Nups (46, 47, 
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58, 68). While the classical basic NLS is still thought to be the most prevalent, 
since its discovery several unrelated NLSs have been identified, although many 
are still poorly characterized (27, 46, 47, 58, 68). Similar to import, the NESs of a 
variety of cargoes have been described, the best characterized, and to date most 
common, being the loosely conserved hydrophobic NES mediated by the export 
karyopherin CRM1 (16, 19, 46, 47, 58, 68).  
 
Common to all members of the Kapβ superfamily, and critical for almost all 
known nuclear import and export pathways, is the ability to interact with the small 
GTPase Ran in its GTP-bound state (19, 46, 47, 58, 68). Localized primarily in 
the nucleus, Ran is an abundant protein capable of switching between GDP and 
GTP-bound states, but possesses low intrinsic activity and requires regulators for 
either GTP hydrolysis or GDP/GTP exchange (19, 46, 47, 58, 68). Karyopherins 
involved in import have a relatively high affinity for RanGTP, where RanGTP 
binding results in dissociation of the karyopherin/cargo complex (19, 46, 47, 58, 
68). Conversely export karyopherins have a low affinity for RanGTP in the 
absence of cargo, and only form stable complexes when both are present (19, 46, 
47, 58, 68). As such, hydrolysis of GTP results in dissociation of the 
exportin/cargo complex (19, 46, 47, 58, 68). The ability of RanGTP to act as 
molecular switch for nucleocytoplasmic transport is dependent on the 
concentration gradient of RanGTP that must exist across the NPC; specifically, 
low concentration in the cytoplasm and high in the nucleus (19, 46, 47, 58, 68). 
This gradient is maintained via the distribution of Ran regulators, with the main 
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GTPase activating proteins, RanGAP and RanBP1, existing in the cytoplasm, 
and the Ran nucleotide exchange factor, RanGEF/RCC1, found primarily bound 
to chromatin in the nucleus (46, 47, 58, 68).  
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Nucleocytoplasmic Transport of HPV16 E7 
 
As discussed above, previous studies have shown 16E7 to act primarily in the 
nucleus, but have also revealed roles in the cytoplasm (4, 24, 35, 49, 54, 67). 
Consistent with these data, 16E7 has been shown to be found throughout the cell, 
but to be primarily localized in the nucleus (2, 28). Interestingly, while facilitated 
nuclear localization is predominately mediated by karyopherin recognition of 
NLS-containing cargo proteins in the cytoplasm and subsequent NPC 
translocation, 16E7 contains neither a canonical, nor any other previously 
characterized NLS (2, 28, 46, 47, 58, 63, 68).  
 
Initial studies performed in the Moroianu lab by Angeline et al. investigated the 
nuclear import of 16E7 through use of in vitro nuclear import assays and in vitro 
isolation assays in the context of both the full-length 16E7 protein, and a pRB-
binding deficient deletion-mutant, fused to GST reporters (2). The study revealed 
that while in vitro nuclear import of 16E7 was dependent on the cytosolic factor 
Ran, it was independent of either importin β or transportin (2). In vitro nuclear 
import assays showed that 16E7 import was independent of its ability to bind 
pRB (2). In addition, in vitro isolation assays revealed that 16E7 does not bind to 
Ran or its import receptor, p10/NTF2 (2). Together, these data suggest that 16E7 
is not imported by ‘piggy-backing’ onto the import mechanisms of Ran (2). These 
results suggest 16E7 entry into the nucleus occurs through a non-classical, Ran 
dependent pathway (2).   
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Subsequent work by the Moroianu lab performed by Knapp et al. further 
characterized 16E7 nucleocytoplasmic transport by analyzing the intracellular 
localization of the 16E7 protein, its three domains, and various mutants, through 
the use of in vitro nuclear import assays and in vivo transient transfections (28). 
Results from the study confirmed in vivo that 16E7 binding to pRB is not required 
for nuclear import and further showed that CKII phosphorylation, likewise, was 
not required for nuclear import in vivo (28). Examination of the N-terminal (aa1-
37, CR1 and CR2) domains of 16E7 revealed a novel NLS (nNLS) in the in vivo 
transient transfection assays (28). Examination of the C-terminal (aa38-98, CR3) 
domain of 16E7 revealed mostly cytoplasmic localization (28). To determine if the 
observed 16cE7 localization was due to the absence of an active NLS or the 
presence of both a weak NLS and a stronger NES, inhibitors of leucine-rich, 
CRM1 mediated, nuclear export were added to the in vivo transient transfection 
assays (28). The addition of either the inhibitor Leptomycin B (LMB) or ratjadone 
(RJA) consistently changed the localization of the 16cE7 from predominantly 
cytoplasmic to predominantly nuclear (28). Examination of the 16cE7 amino acid 
sequence revealed 2 putative, overlapping leucine-rich NES (76IRTLEDLLM84 
and 79LEDLLMGTLGI89) (28). Together these data suggest 16cE7 contains an 
NLS that is overwhelmed by the presence of a stronger NES, and that in the 
context of the full-length 16E7, the N- and C-terminal NLS (nNLS and cNLS) 
work cooperatively to account for the predominantly nuclear localization of 16E7 
(28). Further analysis of the NES identified 76IRTLEDLLM84 as the major NES 
with the downstream LGI sequence enhancing the activity of the main NES (28). 
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Further in vitro analysis of the cNLS showed a sub-region of the CR3 domain (aa 
44-98) that contained the zinc-finger of 16E7 was sufficient to mediate nuclear 
import of a GST reporter in the presence of only exogenous RanGDP (28). 
Together these data suggest that 16E7 can shuttle between the cytoplasm and 
the nucleus and is consistent with the previously described roles of 16E7 in both 
the nucleus and the cytoplasm (28). 
 
While unusual, nuclear import similar to that of 16E7 has been described in the 
literature. Previous studies have described a small number of proteins for which 
import is carrier independent, including MAPK, STAT, HIV-1 Vpr, and RCC1, 
among others (73). Of particular interest was a report characterizing the nuclear 
import of the Human T Lymphotropic Virus Type I (HTLV-1) Tax protein (73). Like 
16E7, nuclear import of HTLV-1 Tax was found to be independent of karyopherin 
carriers (73). More interesting, however, is that, like the 16E7 cNLS, import of the 
Tax protein was found to be dependent on a zinc finger motif (73). This zinc-
binding fold dependent mechanism of nuclear import was initially investigated in 
the Moroianu lab by Piccioli et al. examining the nuclear import of HPV11 E7 (60). 
Through the use of mutagenesis of cysteine residues to disrupt the zinc-binding 
domain, and the use of both in vitro nuclear import assays and in vivo transient 
transfections, Piccioli et al. demonstrated that the integrity of the zinc-binding 
domain was critical for the nuclear localization of HPV11 E7 (60). Further work by 
Piccioli et al. using Phenyl-Sepharose beads to mimic the specificity of FG-Nups 
within the NPC suggested that the mechanism by which HPV11 E7 enters the 
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nucleus is via direct low affinity hydrophobic interactions with FG-Nups, similar to 
the mechanism employed by karyopherins (60). More recent work in the 
Moroianu lab identified a mostly hydrophobic patch of residues within the zinc-
binding domain that, when substituted to alanine, completely disrupted the 
nuclear localization of HPV11 E7 (38). Together these data suggest that the 
mechanism by which the cNLS of HPV16 E7 facilitates nuclear import may be via 
a critical patch of surface exposed hydrophobic residues within the zinc-binding 
domain mediating low affinity interactions with FG-Nups within the NPC (38, 60, 
73). 
 
In this study we continued our characterization of the nucleocytoplasmic 
transport of the high risk HPV16 E7 oncoprotein. We discovered that the zinc-
binding domain within the CR3 domain of HPV16 E7 is essential for cNLS 
function. We further demonstrated that a patch of hydrophobic residues, 
65LRLCV69, within the zinc-binding domain of HPV16 E7 mediates nuclear import 
via direct hydrophobic interaction with the FG repeats of the central nucleoporin, 
Nup62. In addition, we demonstrated that the HPV16 E7 interacts with the 
nuclear export receptor CRM1, and that nuclear export may be modestly 
regulated via phosphorylation of the high risk conserved serine 71 residue.  
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Chapter 2 
Materials and Methods 
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Generation of EGFP and 2xEGFP Fusion Plasmids with HPV16 E7 and 
HPV16 cE7 Containing Different Mutations  
 
EGFP and EGFP-EGFP (2xEGFP) fusion plasmids containing a 16E7 or 16cE7 
insert were obtained previously (28). The zinc conjugating cysteine mutants 
EGFP-16E7C58A, 2xEGFP-16E7C58A, EGFP-16E7CC58AA, 2xEGFP-16E7CC58AA, 
and EGFP-16E7C91A, 2xEGFP-16E7C91A, as well as the conserved cysteine 59 
EGFP-16E7C59A, and 2xEGFP-16E7C59A mutants were generated using the 
QuikChange™ Site-Directed Mutagenesis Kit (Stratagene) with either EGFP-
16E7 or 2xEGFP-16E7 as templates, and the following mutagenesis primer pairs 
(Sigma-Aldrich): 
 C58A  
 Forward: 5’-3’ 
 GATTACAATATTGTAACCTTTGCTTGCAAGTGTGACTCTACGC 
 Reverse: 5’-3’ 
 GCGTAGAGTCACACTTGCAAGCAAAGGTTACAATATTGTAATG 
 C59A 
 Forward: 5’-3’ 
 CAATATTGTAACCTTTTGTGCCAAGTGTGACTCTACGCTTC 
 Reverse: 5’-3’  
 GAAGCGTAGAGTCACACTTGGCACAAAAGGTTACAATATTG 
 C91A 
 Forward: 5’-3’  
 CACACTAGGAATTGTGGCCCCCATCTGTTCTCAG 
 Reverse: 5’-3’ 
	   23	  
 CTGAGAACAGATGGGGGCCACAATTCCTAGTGTG 
 CC58AA 
 Forward: 5’-3’  
 CAATATTGTAACCTTTGCCGCCAAGTGTGACTCTACGC 
 Reverse:  5’-3’ 
 GCGTAGAGTCACACTTGGCGGCAAAGGTTACAATATTG 
 
The EGFP-16E7LRLCV65AAAAA, 2xEGFP-16E7LRLCV65AAAAA, EGFP-16E7R66A, and 
2xEGFP-16E7R66A mutants were generated using the QuikChange™ Site-
Directed Mutagenesis Kit with either EGFP-16E7 or 2xEGFP-16E7 as templates, 
and the following mutagenesis primer pairs (Integrated DNA Technologies): 
 LRLCV65AAAAA 
 Forward: 5’-3’ 
  GTTGCAAGTGTGACTCTACGGCCGCCGCCGCCGCACAAAGCACACACGTAGAC 
 Reverse: 5’-3’ 
 GTCTACGTGTGTGCTTTGTGCGGCGGCGGCGGCCGTAGAGTCACACTTGCAAC 
 R66A 
 Forward: 5’-3’ 
 GTGACTCTACGCTTGCGTTGTGCGTACAAAG 
 Reverse: 5’-3’ 
 CTTTGTACGCACAACGCAAGCGTAGAGTCAC 
 
The EGFP-16E7S71A, EGFP-16cE7S71A, EGFP-16cE7S71D, 2xEGFP-16cE7S71D, 
EGFP-16cE7S71E, and 2xEGFP-16cE7S71E mutants were generated using the 
QuikChange™ Site-Directed Mutagenesis Kit with EGFP-16E7, EGFP-16cE7 or 
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2xEGFP-16cE7 as templates, and the following mutagenesis primer pairs 
(Sigma-Aldrich, S71A and S71D; Integrated DNA Technologies, S71E): 
 S71A 
 Forward: 5’-3’ 
 CTTCGGTTGTGCGTACAAGCAACACACGTAGACATTCG 
 Reverse: 5’-3’ 
 CGAATGTCTACGTGTGTTGCTTGTACGCACAACCGAAG 
 S71D 
 Forward: 5’-3’ 
 CTTCGGTTGTGCGTACAAGATACACACGTAGACATTCG 
 Reverse: 5’-3’ 
 CGAATGTCTACGTGTGTATCTTGTACGCACAACCGAAG 
 S71E 
 Forward: 5’-3’ 
 GCTTCGGTTGTGCGTACAAGAAACACACGTAGACATTCGTAC 
 Reverse: 5’-3’ 
 GTACGAATGTCTACGTGTGTTTCTTGTACGCACAACCGAAGC 
 
All mutant plasmids were transformed into XL1-Blue competent cells (Agilent 
Technologies) and extracted using Quantum Prep® Plasmid MidiPrep kit 
(BioRad) according to manufacturer’s protocol. All purified plasmids were 
sequenced for verification (Eurofins MWG) and maintained in stock cultures of 
850 µl bacteria and 150 µl sterile glycerol at -80°C before use in transient 
transfection experiments. 
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Transient Expression of EGFP Fusion Proteins and Confocal Fluorescence 
Microscopy Analysis 
 
In vivo transient transfection experiments were performed on subconfluent HeLa 
cells (ATCC) as previously described (28, 33, 38, 60). Cells were plated on 12 
mm poly-L-lysine-coated glass coverslips to 50-70% confluency 24 h prior to 
transfection. Cells in each well were then transfected with a mixture of 1-2 µg of 
the corresponding EGFP or 2xEGFP fusion plasmid (as indicated in the Figure 
legends) and 4 µl of FuGENE 6 Transfection Reagent (Roche Applied Science) 
in 96 µl of DMEM that had been premixed and allowed to equilibrate for 20 min. 
Media was changed to DMEM with 10% fetal bovine serum (FBS) and 1% 
penicillin-streptomycin after 6 hours and the cells were fixed 22 to 24 hours after 
the initial transfection with 3.7% formaldehyde in phosphate buffered saline 
(PBS) for 10 min. Coverslips were mounted using Vectashield-DAPI mounting 
medium (Vector Labs) to visualize the nuclei by DAPI staining. The slides were 
examined under 630x magnification by confocal fluorescence microscopy using a 
Leica TCS Sp5 broadband confocal microscope and representative images were 
taken using the Leica LAS AF software (Leica Microsystems). 
 
Intracellular localization phenotypes of the different EGFP fusion proteins were 
scored as predominantly nuclear, pancellular, or predominantly cytoplasmic, as 
visually observed under 630x magnification via confocal fluorescence microscopy 
for each of the transfection experiments. The data from between three and seven 
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experiments (as indicated in the Figure legends) were used for the quantitative 
analysis. Graphical representations for each quantitative analysis display 
average values with standard deviations.  
 
Immunoblotting 
 
To ensure that the EGFP and 2xEGFP fusion proteins were expressed at similar 
levels and not degraded, immunoblot analysis was used. As above, HeLa cells 
were plated to 50-70% confluency 24 h prior to transfection. Cells in each well 
were then transfected with a mixture of 1-2 µg of the corresponding EGFP or 
2xEGFP fusion plasmid (as indicated in the Figure legends) and 4 µl of FuGENE 
6 Transfection Reagent in 96 µl of DMEM that had been premixed and allowed to 
equilibrate for 20 min. Media was changed to DMEM with 10% FBS and 1% 
penicillin-streptomycin after 6 hours. Between 22 and 24 h post transfection, cells 
were washed with PBS, lysed in standard SDS-PAGE buffer, boiled for 10 
minutes. Cell lysates were electrophoretically separated on a 12% 
polyacrylamide gel at 45 mA and then transferred to a nitrocellulose membrane 
for 45 min at 75 V. Once the proteins had transferred to the nitrocellulose 
membrane, they were stained with 1xPonceau and blocked on a rocker for 1 h at 
room temperature in 5% non-fat milk in PBS. Blots were subsequently washed 3x 
with PBS, then incubated in anti-EGFP primary antibody (Clonetech) at a 1:1000 
dilution in 5% Milk/PBS for 1 h at room temperature on a rocker. Following three 
more washes, HRP conjugated goat anti-mouse secondary antibody (Santa Cruz 
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Biotechnology) was added and incubated on a rocker for 30 min at room 
temperature. Following a final three washes, blots were developed using 
HyGLO™ Chemiluminescent HRP Antibody Detection Reagent (Denville 
Scientific) and exposed to HyBlot CL™ autoradiography film (Denville Scientific). 
 
 
Preparation of GST-16cE7 Fusion Proteins with Hydrophobic Residue or 
Arginine 66 Mutations 
 
The GST-16cE7 plasmid was obtained previously (28). The GST-16cE7R66A and 
GST-16cE7LRLCV65AAAAA mutants were generated using the QuikChange™ Site-
Directed Mutagenesis Kit with GST-16cE7 as the template, and the mutagenesis 
primer pairs as indicated above. The mutant plasmids were transformed into 
XL1-Blue competent cells and extracted using Quantum Prep® Plasmid MidiPrep 
kit. All purified plasmids were sequenced for verification (Eurofins MWG) and 
maintained in stock cultures of 850 µl bacteria and 150 µl sterile glycerol at -80°C. 
 
For protein expression and purification, each GST-16cE7 plasmid was used to 
transform E. coli BL21 CodonPlus (Agilent Technologies). Bacteria were then 
induced with 1mM IPTG for 3 h at 37°C, and each mutant protein was purified in 
its native state on glutathione-Sepharose beads (GE Healthcare) using a 
standard procedure. The GST-M9 positive control containing the NLS of 
hnRNPA1 was prepared as previously described (2). All purified GST fusion 
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proteins were dialyzed in transport buffer (20 mM HEPES-KOH pH 7.3, 110mM 
potassium acetate, 2 mM magnesium acetate, 1 mM EGTA, and 2 mM DTT) plus 
the protease inhibitors leupeptin and aprotinin. Purified and dialyzed proteins 
were aliquoted and stored at -80°C. Prior to use, all proteins were checked for 
purity and lack of proteolytic degradation by SDS-PAGE and Coomassie Blue 
staining. 
 
In Vitro Nuclear Import Assays 
 
Nuclear import assays were performed according to previously established 
protocols (1, 2, 26, 27, 33, 51-53, 60). Subconfluent HeLa cells, grown on 12 mm 
poly-L-lysine-coated glass coverslips for 24 h, were permeablized with 70 µg/µl 
digitonin for 5 min on ice to selectively permeabilize the plasma membrane while 
leaving the nuclear envelope intact. As a result, these digitonin-permeabilized 
cells will retain intact import-competent nuclei while being largely depleted of 
cytosolic transport factors. After three washes with cold transport buffer, all 
import reactions were incubated with the import mixture for 30 minutes. Each 
import mixture contained an energy regenerating system (1 mM GTP, 1 mM ATP, 
5 mM phosphocreatine, and 0.4U creatine phosphokinase) and the different GST 
fusion proteins (as indicated in the Figure legend). In addition, each import 
contained either 3 ng/µl BSA in transport buffer, or HeLa cytosol. Final import 
reaction volumes were adjusted to 20 µl with transport buffer. 
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For visualization of nuclear import, the GST fusion proteins were detected by 
immunofluorescence with a goat anti-GST antibody.  Once the import assays 
were completed, cells were washed, fixed with 3.7% formaldehyde in PBS for 10 
min on ice followed by methanol treatment for 3 min at -20°C. Cells were 
subsequently blocked for 1 h at room temperature with 3% BSA/0.1% Tween in 
PBS to reduced non-specific antibody binding. Cells were then incubated for 1 h 
with a 1:200 dilution of goat anti-GST primary antibody (GE Healthcare) at room 
temperature. Following three washes with 3% BSA/0.1% Tween, cells were 
incubated with a 1:100 dilution of FITC conjugated rabbit anti-Goat secondary 
antibody (Sigma) for 30 min at room temperature. Following a final three washes, 
coverslips were mounted using Vectashield-DAPI mounting medium to identify 
the nuclei by DAPI staining. Nuclear import was assessed under 630x 
magnification by confocal fluorescence microscopy using a Leica TCS Sp5 
broadband confocal microscope and representative images were taken using the 
Leica LAS AF software. 
 
Preparation of GST-CRM1 and GST-Nup62N 
 
The GST-CRM1 and GST-Nup62N plasmids were the kind gifts of Dr. Jorgen 
Kjems and Dr. Nabeel Yaseen. Both the GST-CRM1 and GST-Nup62N plasmids 
were used to transform E. coli BL21 CodonPlus. Following bacterial induction 
with 1mM IPTG for 3 h at 37°C, each GST fusion protein was purified in its native 
state on Glutathione-Sepharose beads and dialyzed as described previously. 
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Purified and dialyzed proteins were aliquoted and stored at -80°C. Prior to use, 
all proteins were checked for purity and lack of proteolytic degradation by SDS-
PAGE and Coomassie Blue staining. 
 
Isolation Assays 
 
Prior to performing the isolation assays, GST-CRM1 and GST immobilized on 
glutathione-Sepharose beads were analyzed by SDS-PAGE and Coomassie blue 
staining to ensure the proteins were intact and bound to the beads at similar 
levels. Cells grown to 50-70% confluency in 25 mm2 flasks were transfected with 
a mixture of EGFP-16cE7, EGFP-16E7NESRev (as a positive control), or EGFP 
(as a negative control) and FuGENE 6 Transfection Reagent in DMEM that had 
been premixed and allowed to equilibrate for 20 min. Media was changed to 
DMEM with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin after 6 
hours. Between 22 and 24 h post transfection cells were lysed for 30 min with 
0.001% Triton X-100 in PBS with 5 mM EDTA and the protease inhibitors PMSF, 
leupeptin and aprotinin at room temperature with rotation. Lysates were 
subsequently spun down at 17,000x g for 30 min at 4°C to remove cellular debris. 
Supernatants containing the expressed EGFP fusion proteins and 1 mM GTP-γs 
were incubated with either GST-CRM1 or GST immobilized on glutathione-
Sepharose beads for 1 h at 4°C. After washing three times with transport buffer 
supplemented with protease inhibitors to remove nonspecific binding, the bound 
proteins were eluted with SDS-sample buffer and electrophoretically separated 
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on a 12% polyacrylamide at 45 mA then transferred to a nitrocellulose membrane 
for 45 min at 75 V. Once the proteins had transferred to the nitrocellulose 
membrane they were stained with 1xPonceau and blocked on a rocker for 1 h at 
room temperature in 5% non-fat milk in PBS. Blots were subsequently washed 3x 
with PBS then incubated in anti-EGFP primary antibody (Clonetech) at a 1:1000 
dilution in 5% Milk/PBS for 1 hour at room temperature on a rocker. Following 
three more washes, HRP conjugated goat anti-mouse secondary antibody was 
added and incubated on a rocker for 30 min at room temperature. Following a 
final three washes, blots were developed using HyGLO™ Chemiluminescent 
HRP Antibody Detection Reagent and exposed to HyBlot CL™ autoradiography 
film.  
 
Prior to performing the isolation assays, GST-Nup62N and GST immobilized on 
glutathione-Sepharose beads were analyzed by SDS-PAGE and Coomassie blue 
staining to ensure the proteins were intact and bound to the beads at similar 
levels. HeLa cell lysates containing the expressed EGFP-16E7, EGFP-
16E7LRLCV65AAAAA, EGFP-16E7R66A, and EGFP (as a negative control), prepared 
in a manner identical to as described above, were incubated with GST-Nup62N 
or GST immobilized on glutathione-Sepharose beads for 1 h at 4°C. As a positive 
control for binding to Nup62N, binding of the Kap β2 nuclear import receptor to 
GST-Nup62N was analyzed by incubating untransfected HeLa cell lysate with 
GST-Nup62N or GST. After washing the beads to remove nonspecific binding, 
the bound proteins were analyzed by immunoblotting with an either an EGFP 
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antibody as described above or with a Kap β2 antibody (Santa Cruz 
Biotechnology) for the positive control. 
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Chapter 3 
Characterization of the cNLS of HPV16 E7 Oncoprotein 
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The Zinc Binding Domain of HPV16 E7 is Essential for Nuclear Import 
 
As previously discussed, prior work in the Moroianu lab has shown that, despite 
having no canonical NLS, HPV16 E7 is imported into the nucleus in a Ran-
dependent, Karyopherin independent fashion (2). Subsequent work in the 
Moroianu lab revealed the presence of a C-terminal NLS within the CR3 domain 
of E7 containing the zinc-binding fold (consisting of two copies of Cys-X-X-Cys 
sequence motif separated by 29 amino acids, and where all four cysteines 
interact with zinc) (28). Furthermore, studies examining the nuclear import of 
other HPV oncoproteins that enter into the nucleus independent of karyopherin 
import receptors, including HPV11 E7 in the Moroianu lab, have implicated a 
potential role of this zinc-binding domain within the CR3 domain of HPV16 E7 in 
directly facilitating nuclear import (38, 60, 73). To examine the possibility that the 
intact zinc-binding domain of HPV16 E7 was essential for the nuclear import 
activity of the cNLS of HPV16 E7, disruption of the zinc-binding fold was 
performed through the site-directed mutagenesis of cysteine residues in each of 
the two copies of Cys-X-X-Cys in the context of EGFP-16E7 and 2xEGFP-16E7 
(Figure 1). 
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Figure 1: Schematic Overview of the Zinc Binding Domain Mutants 
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After generating the cysteine mutants affecting zinc conjugation, the EGFP-
16E7CC58AA and EGFP-16E7C91A mutants, as well as the wild type EGFP-16E7 
and EGFP control, were transiently transfected into HeLa cells and their resultant 
sub-cellular localizations were examined via confocal fluorescence microscopy 
(Figure 2). Qualitative examination of the localization of the zinc conjugating 
cysteine mutants in contrast to the localization of the wild-type EGFP-16E7 
protein shows that, while EGFP-16E7 localizes primarily to the nucleus (panels 
2A, 2B and 2C), both EGFP-16E7CC58AA (panels 2D, 2E, and 2F) and EGFP-
16E7C91A (panels 2G, 2H and 2I) exhibit a predominantly pancellular localization. 
These data indicated that, while disruption of the zinc-binding domain in the 
context of EGFP-16E7 was able to shift localization from mostly nuclear to 
pancellular, disruption of the zinc-binding domain was insufficient to prevent 
either EGFP-16E7CC58AA or EGFP-16E7C91A from gaining entry to the nucleus. 
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Figure 2: Mutations of the Zinc Conjugating Cysteines Alter the 
Localization of EGFP-16E7 
HeLa cells were transfected with either EGFP-16E7 wild type (panels A-C), EGFP-16E7CC58AA 
(panels D-F), EGFP-16E7C91A (panels G-I), or EGFP (panels J-L) plasmids and examined by 
confocal fluorescence microscopy at 24 h post transfection. Panels B, E, H and K represent the 
fluorescence of the EGFP and panels A, D, G and J the DAPI staining of the nuclei. Panels C, F, I, 
and L represent a merge of EGFP and DAPI fluorescence. 
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While the pancellular localization of EGFP-16E7CC58AA and EGFP-16E7C91A in 
Figure 2 suggests EGFP-16E7 is able to enter the nucleus without an intact zinc-
binding domain, it was unclear as to if this is a result of passive diffusion of the 
EGFP-16E7 mutants across the NPC, or of the cNLS of 16E7 being at least 
partially independent of the intact zinc-binding domain for its function. In order to 
distinguish between these two possibilities, identical zinc conjugating cysteine 
mutants to those previously described were generated in the context of 2xEGFP-
16E7 to exceed the limit for passive diffusion across the NPC. The 2xEGFP-
16E7CC58AA and 2xEGFP-16E7C91A mutants, along with the 2xEGFP-16E7 wild 
type and 2xEGFP control, were transiently transfected into HeLa cells and their 
resultant sub-cellular localizations were examined via confocal fluorescence 
microscopy using identical methodology to that used for the previous experiment 
(Figure 3). Qualitative examination of the localization of the zinc conjugating 
cysteine mutants in contrast to that of the wild-type 2xEGFP-16E7 shows a more 
dramatic shift in localization than that seen for the EGFP-16E7 mutants. 
Whereas, like EGFP-16E7, 2xEGFP-16E7 exhibited predominantly nuclear 
localization (panels 3A, 3B and 3C), the localization of 2xEGFP-16E7CC58AA 
(panels 3D, 3E and 3F) and 2xEGFP-16E7C91A (panels 3G, 3H and 3I) exhibited 
predominantly cytoplasmic localization in contrast to the pancellular localization 
of their EGFP-16E7 counterparts. These data suggest the activity of the cNLS of 
HPV16 E7 is dependent upon an intact zinc-binding domain and that the 
pancellular localization observed in the EFGP-16E7 zinc conjugating cysteine 
mutants was due to passive diffusion across the NPC. 
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Figure 3: Mutations of the Zinc Conjugating Cysteines Alter the 
Localization of 2xEGFP-16E7 
HeLa cells were transfected with either 2xEGFP-16E7 wild type (panels A-C), 2xEGFP-
16E7CC58AA (panels D-F), 2xEGFP-16E7C91A (panels G-I), or 2xEGFP (panels J-L) plasmids and 
examined by confocal fluorescence microscopy at 24 h post transfection. Panels B, E, H and K 
represent the fluorescence of the EGFP and panels A, D, G and J the DAPI staining of the nuclei. 
Panels C, F, I, and L represent a merge of EGFP and DAPI fluorescence. 
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In addition to qualitative assessment of the predominant localization phenotype 
of the EGFP-16E7 and 2xEGFP-16E7 zinc conjugating cysteine mutants, 
quantitative analysis of the phenotypic distribution of each of the transiently 
transfected HeLa cell populations in the EGFP-16E7 and 2xEGFP-16E7 
experimental series was performed. In each case HeLa cells transiently 
transfected with either the EGFP-16E7, 2xEGFP-16E7 wild type or the respective 
zinc conjugating cysteine mutants were examined via confocal fluorescence 
microscopy and every positively transfected cell within the given population, as 
evidenced by EGFP fluorescence, was scored as either predominantly nuclear, 
pancellular, or predominantly cytoplasmic. The results of five independent 
experiments were averaged and compared, as can be seen graphically in Figure 
4 and as raw data in Table 1. These quantitative data serve to support the 
conclusions drawn from the previous qualitative assessment. These data show 
that roughly 85% +/- 2.4% of the cells transfected with EGFP-16E7 wild type 
exhibit a predominantly nuclear phenotype and to 14.8% +/- 2.2% exhibit a 
pancellular phenotype. Mutation of the zinc conjugating cysteines in the context 
of the EGFP-16E7 in turn show 83.2% +/- 4.1% of the cells in the EGFP-
16E7CC58AA population and 85.8% +/- 6.9% of the cells in the EGFP-16E7C91A 
exhibit a pancellular localization, with 14.4% +/- 3.6% and 12.2% +/- 6% 
exhibiting a predominantly nuclear phenotype, respectively. As seen in the 
qualitative assessment, the phenotypic shift in the cell populations of the 
2xEGFP-16E7 zinc conjugating cysteine mutants compared to the wild type was 
more severe. These data show that the 77.6%+/-4.7% of the cells transfected 
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with 2xEGFP-16E7 exhibited a predominantly nuclear phenotype as compared to 
21% +/- 2.9% that exhibited pancellular localization. In contrast to mutation of the 
zinc conjugating cysteines in the context of the EGFP-16E7, no significant 
number of cells transfected with either 2xEGFP-16E7CC58AA or 2xEGFP-16E7C91A 
exhibited predominantly nuclear localization. In contrast, 86.4% +/- 3.6% of 
2xEGFP-16E7CC58AA and 89.8% +/- 5.1% of 2xEGFP-16E7C91A transfected cells 
exhibited predominantly cytoplasmic localization with the remainder, 13.4% +/- 
3.6% and 9.8% +/- 5%, respectively, phenotypically scored as pancellular.  
Together these data support the conclusions drawn from the previous qualitative 
analyses suggesting that the activity of the cNLS of HPV16 E7 is dependent 
upon an intact zinc-binding domain. 
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Figure 4: Disruption of the Zinc Finger Alters the Localization of EGFP-
16E7 and 2xEGFP-16E7 
The data from five experiments using EGFP-16E7, EGFP-16E7CC58AA EGFP-16E7C91A, EGFP,  
2xEGFP-16E7, 2xEGFP-16E7CC58AA 2xEGFP-16E7C91A, and 2xEGFP and plasmids have been 
used for the quantification graphic representation of the phenotypic distribution of transfected 
HeLa cells. Blue bars represent cells exhibiting predominant nuclear localization; red bars 
represent cells exhibiting pancellular localization; yellow bars represent cells exhibiting 
predominant cytoplasmic localization. 
 
	   43	  
In addition to demonstrating that the zinc-binding domain is essential for nuclear 
import of HPV11 E7, previous work in the Moroianu lab on HPV11 E7 
demonstrated that a cysteine residue at position 59, conserved between the high 
risk and low risk HPVs, was involved in cNLS function beyond its ability to 
conjugate the zinc ion (60). To examine if this conserved cysteine residue was 
able to perform a similar function in HPV16 E7, site directed mutagenesis was 
used to generate a pair of single amino acid substitutions of the n-terminal 
cysteines within the zinc-binding domain in the context of both EGFP-16E7 and 
2xEGFP-16E7, schematically represented in Figure 1. Initially the EGFP-16E7 
single amino acid mutants EGFP-16E7C58A and EGFP-16E7C59A, as well as the 
wild type EGFP-16E7 and EGFP control, were transiently transfected into HeLa 
cells and their resultant sub-cellular localizations were examined via confocal 
fluorescence microscopy, (Figure 5). Qualitative analysis of the localization of the 
single amino acid mutants in contrast to the localization of the wild-type EGFP-
16E7 protein shows that, as previously demonstrated, EGFP-16E7 localizes 
primarily to the nucleus (panels 5A, 5B and 5C), but unlike what was observed 
for the previous zinc conjugating mutants, both EGFP-16E7C58A (panels 5D, 5E, 
and 5F) and EGFP-16E7C59A (panels 5G, 5H and 5I) exhibit predominantly 
nuclear localization as well. These data seem to indicate that while the cysteine 
59 residue may compensate for the loss of the cysteine 58 residue in conjugating 
the zinc ion and maintaining the zinc-binding domain, it does not seem to play 
any additional role in cNLS function. 
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Figure 5: Single Amino-Acid Substitution of the N-terminal Cysteines within 
the Zinc Binding Domain Alter the Localization of EGFP-16E7 
HeLa cells were transfected with either EGFP-16E7 wild type (panels A-C), EGFP-16E7C58A 
(panels D-F), EGFP-16E7C59A (panels G-I), or EGFP (panels J-L) plasmids and examined by 
confocal fluorescence microscopy at 24 h post transfection. Panels B, E, H and K represent the 
fluorescence of the EGFP and panels A, D, G and J the DAPI staining of the nuclei. Panels C, F, I, 
and L represent a merge of EGFP and DAPI fluorescence. 
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In addition to examining the role of the cysteine 59 residue in the context of 
EGFP-16E7, an identical pair of mutants was prepared in the context of 2xEGFP-
16E7. These mutants, as well as 2xEGFP-16E7 wild type and 2xEGFP, were 
transiently transfected into HeLa cells and their resultant sub-cellular 
localizations were examined via confocal fluorescence microscopy (Figure 6). 
While both 2xEGFP-16E7 wild type (panels 6A, 6B and 6C) and 2xEGFP-
16E7C59A (panels 6G, 6H, and 6I) exhibit predominantly nuclear localization, 
2xEGFP-16E7C58A (panels 6D, 6E, and 6F) exhibited pancellular localization 
instead. Qualitative assessment of these data seem to confirm that the 
conserved cysteine 59 residue does not affect cNLS function in a manner similar 
to what was previously observed in HPV11 E7 (60). In addition, in the context of 
2xEGFP-16E7, cysteine 59 seems less able to compensate for the loss of the 
zinc conjugating cysteine 58 in maintaining the zinc-binding domain necessary 
for cNLS function. 
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Figure 6: Single Amino-Acid Substitution of the N-terminal Cysteines within 
the Zinc Binding Domain Alter the Localization of 2xEGFP-16E7 
HeLa cells were transfected with either 2xEGFP-16E7 wild type (panels A-C), 2xEGFP-16E7C58A 
(panels D-F), 2xEGFP-16E7C58A (panels G-I), or 2xEGFP (panels J-L) plasmids and examined by 
confocal fluorescence microscopy at 24 h post transfection. Panels B, E, H and K represent the 
fluorescence of the EGFP and panels A, D, G and J the DAPI staining of the nuclei. Panels C, F, I, 
and L represent a merge of EGFP and DAPI fluorescence. 
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While qualitative data suggest that the conserved cysteine 59 residue does not 
play a direct role in the function of the HPV16 cNLS, a quantitative analysis of the 
phenotypic distribution of each of the transiently transfected HeLa cell 
populations in the EGFP-16E7 and 2xEGFP-16E7 single amino acid mutant 
series may indicate a more modest role for the cysteine 59 residue of HPV16 E7 
compared to what had been previously observed for HPV11 E7 (60). For these 
experiments, HeLa cells transiently transfected with either the EGFP-16E7, 
2xEGFP-16E7 wild type or the respective single amino acid mutants were 
examined via confocal fluorescence microscopy and every positively transfected 
cell within the given population, as evidenced by EGFP fluorescence, was scored 
as either predominantly nuclear, pancellular, or predominantly cytoplasmic. The 
results of five independent experiments were averaged and compared, seen 
graphically in Figure 7 and as raw data in Table 1. These quantitative data 
implicate a modest role for cysteine 59 in cNLS function that was not clear in the 
qualitative analysis. In the context of EGFP-16E7, while the major cellular 
phenotype of EGFP-16E7C58A and EGFP-16E7C59A are predominantly nuclear like 
EGFP-16E7 wildtype (55.3% +/- 5.7% and 69.3% +/-9.5% compared to 85% +/- 
2.4%, respectively), there is a substantial increase in the number of cells 
exhibiting a pancellular phenotype (43.8% +/-5.9% and 30.3% +/- 9.3% 
compared to 14.8% +/-2.2%, respectively). These data support the qualitative 
analysis of the 2xEGFP-16E7 single amino acid mutants in suggesting that the 
cysteine 59 residue is only able to partially compensate for the loss of cysteine 
58 in the conjugation of zinc and in maintaining the zinc-binding domain and 
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associated cNLS function. However, unlike what was observed in the qualitative 
experiments, these data indicate that loss of the cysteine 59 residue itself has a 
modest effect on the proportion of cells exhibiting a predominantly nuclear 
phenotype, and may suggest that cysteine 59 does have a modest direct effect 
on cNLS function. Similar to what was seen for the zinc conjugating cysteine 
mutants, quantitative analysis of the single amino acid mutants in the context of 
2xEGFP-16E7 exhibit a more severe shift in the phenotypic distribution of the 
mutants in comparison to the 2xEGFP-16E7 wild type protein. Consistent with 
what was observed in the qualitative assay, the majority 2xEGFP-16E7 wild type 
and 2xEGFP-16E7C59A cells exhibited predominantly nuclear localization (77.6% 
+/- 4.7% and 57.3% +/- 11.1%, respectively) whereas only a very small number 
of 2xEGFP-16E7C58A expressing cells (5% +/- 2.9%) exhibited similar localization. 
In contrast the majority of 2xEGFP16E7C58A and a moderate proportion 2xEGFP-
16E7C59A expressing cells demonstrated pancellular localization compared to 
2xEGFP-16E7 wild type (66.3% +/- 18.6% and 38% +/- 9.1% compared to 21% 
+/- 2.9%, respectively). In addition, a relatively large number of 2xEGFP-
16E7C58A and, to a much lesser extent, 2xEGFP-16E7C59A expressing cells 
demonstrated predominantly cytoplasmic localization compared to the extremely 
small number of 2xEGFP-16E7 wild type expressing cells exhibiting similar 
localization (28.8% +/-18.8% and 4.5% +/-3.3% compared to 1.4% +/- 2.6%, 
respectively). These data further support the conclusion that cysteine 59 can only 
partially compensate for the loss of cysteine 58 in the conjugation of the zinc ion 
and maintenance of the zinc-binding domain, but also that, as seen in the 
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quantitative analysis of the EGFP-16E7 single amino acid mutants, the cysteine 
59 residue may modestly affect cNLS function. Together these data suggest the 
conserved cysteine 59 residue of HPV16 E7 can partially compensate for the 
loss of cysteine 58 in conjugating zinc and maintaining the zinc-binding domain 
and that, while more modest a role than that of HPV11 E7, the conserved 
cysteine 59 residue of HPV16 E7 directly affect cNLS function. 
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Figure 7: Single Amino-Acid Substitutions of N-Terminal Cysteines within 
the Zinc Finger Alter the Localization of EGFP-16E7 and 2xEGFP-16E7 
The data from five experiments using EGFP-16E7, EGFP-16E7C58A EGFP-16E7C59A, EGFP,  
2xEGFP-16E7, 2xEGFP-16E7C58A 2xEGFP-16E7C59A, and 2xEGFP and plasmids have been used 
for the quantification graphic representation of the phenotypic distribution of transfected HeLa 
cells. Blue bars represent cells exhibiting predominant nuclear localization; red bars represent 
cells exhibiting pancellular localization; yellow bars represent cells exhibiting predominant 
cytoplasmic localization. 
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n=5 Mostly Nuclear Pan Cellular Mostly Cytoplasmic 
1xEGFP-16E7wt 1332 230 6 
1xEGFP-16E7 CC58AA 243 1480 46 
1xEGFP-16E7 C58A 711 546 10 
1xEGFP-16E7 C59A 574 279 4 
1xEGFP-16E7 C91A 151 1204 28 
1xEGFP 0 1571 0 
2xEGFP-16E7wt 865 235 15 
2xEGFP-16E7 CC58AA 4 195 1292 
2xEGFP-16E7 C58A 72 963 308 
2xEGFP-16E7 C59A 680 392 33 
2xEGFP16E7 C91A 5 177 1495 
2xEGFP 1 215 1029 
 
 
Table 1: Quantitative Analysis of the Intracellular Localizations of Zinc-
Finger Disruption Mutants 
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As a final control to ensure that the results observed were not due to degradation 
of any of the EGFP-16E7 or 2xEGFP-16E7 proteins, immunoblot analysis with an 
anti-EGFP antibody of all the EGFP-16E7 and 2xEGFP-16E7 wild type and 
mutant proteins indicated was performed (Figure 8). These data indicate that, 
while all wild type and mutant EGFP-16E7 proteins are intact and expressed at 
the correct molecular weight, both the wild type and mutant 2xEGFP-16E7 
proteins exhibit evidence of some proteolytic degradation. While these data 
support the results of both the qualitative and quantitative experiments on the 
EGFP-16E7 mutants, they suggest that some of the shift in localization observed 
for the 2xEGFP-16E7 mutants may have been due to degradation rather than 
solely due as a result of cysteine residue substitution. 
 
In total, these data suggest that, similar to what has been previously observed for 
HPV11 E7, the zinc-binding domain within the CR3 domain of HPV16 E7 is 
essential for cNLS function. In addition these data suggest the conserved 
cysteine 59 residue of HPV16 E7 modestly affects cNLS function beyond its 
limited ability to conjugate zinc in the absence of the cysteine 58 residue. 
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Figure 8: EGFP-16E7 and 2xEGFP-16E7 Zinc Finger Mutants are Properly 
Expressed in HeLa Cells 
HeLa cells were transfected with EGFP-16E7 (lane 1), EGFP-16E7C58A (lane 2), EGFP-16E7C59A 
(lane 3), EGFP-16E7CC58AA (lane 4), EGFP-16E7C91A (lane 5), EGFP (lane 6), 2xEGFP-16E7 
(lane 7), 2xEGFP-16E7C58A (lane 8), 2xEGFP-16E7C59A (lane 9), 2xEGFP-16E7CC58AA (lane 10), 
2xEGFP-16E7C91A (lane 11), or 2xEGFP (lane 12) plasmids. Cell lysates were prepared 24 h post 
transfection and probed with an EGFP antibody.  
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Hydrophobic Residues within the Zinc-Binding Domain are Essential for 
the Nuclear Localization of HPV16 E7 
 
Previous reports have indicated that it is the surface hydrophobicity of 
karyopherins that is sufficient to provide access to the NPC and that translocation 
is achieved through a series of non-specific interactions between short 
hydrophobic patches on the surface of the karyopherins and the FG-Nups within 
the NPC (50). Previous work in the Moroianu lab examining the mechanism by 
which the zinc-binding domain mediated the function of the cNLS demonstrated 
that a small mostly hydrophobic patch of amino acids between within the zinc-
binding domain, 65VRLVV69, was required for the nuclear localization of HPV11 
E7 (38). A small hydrophobic patch within the zinc-binding domain of HPV16 E7, 
65LRLCV69, has significant homology to the previously characterized patch in 
HPV11 E7. To examine the possibility that this hydrophobic patch of amino acids 
within the zinc-binding domain of HPV16 E7 is responsible for mediating its 
nuclear import site-directed mutagenesis was used to replace all five amino acids 
with alanines in the context of EGFP-16E7, 2xEGFP-16E7, and GST-16cE7. In 
addition, site directed mutagenesis was also used to generate an additional 
mutant substituting the charged arginine residue at position 66 with an alanine in 
each of the previously mentioned contexts. A schematic representation of both 
the hydrophobic and the arginine residue mutants can be seen in Figure 9. 
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Figure 9: Schematic Overview of Hydrophobic Amino Acid and R66A 
Mutants 
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After generating both the EGFP-16E7LRLCV65AAAAA and the EGFP-16E7R66A 
mutants, each, along with the wild type EGFP-16E7 and EGFP control, were 
transiently transfected into HeLa cells and their resultant sub-cellular 
localizations were examined via confocal fluorescence microscopy (Figure 10). 
Identical to what was seen in previous experiments, EGFP-16E7 wild type 
(panels 10A, 10E and 10I) exhibited predominantly nuclear localization. This 
predominantly nuclear localization was not observed however upon mutation of 
the hydrophobic residue patch. Cells expressing the EGFP-16E7LRLCV65AAAAA 
(panels 10B, 10F and 10J) instead exhibited a pancellular phenotype. 
Interestingly, cells expressing EGFP-16E7R66A (panels 10C, 10G and 10K) 
exhibited no change in localization in comparison to the wild type EGFP-16E7 
expressing cells and had a predominantly nuclear phenotype. These data 
suggest that, similar to that of HPV11 E7, these hydrophobic residues of HPV16 
E7 are responsible, at least in part, for the nuclear localization of EGFP-16E7 
whereas the positively charged arginine residue plays no role in the function of 
the cNLS. 
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Figure 10: Mutation of Hydrophobic Residues within the Zinc Binding 
Domain of EGFP-16E7 Alters the Localization in Transiently Transfected 
HeLa Cells 
HeLa cells were transfected with either EGFP-16E7 wild type (panels A, E, I), EGFP-
16E7LRLCV65AAAAA (panels B, F, J), EGFP-16E7R66A (panels C, G, K), or EGFP (panels D, H, L) 
plasmids and examined by confocal fluorescence microscopy at 24 h post transfection. Panels A-
D represent DAPI staining of the nuclei, panels E-H represent EGFP fluorescence, and panels I-L 
represent the merge of EGFP and DAPI fluorescence. 
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A quantitative analysis of the phenotypic distribution of each of the transiently 
transfected HeLa cell populations was performed in addition to a qualitative 
assessment of the predominant localization phenotype of cells expressing either 
EGFP-16E7LRLCV65AAAAA or EGFP-16E7R66A. In each case HeLa cells transiently 
transfected with either EGFP-16E7 wild type, EGFP, EGFP-16E7LRLCV65AAAAA or 
EGFP-16E7R66A were examined via confocal fluorescence microscopy and every 
positively transfected cell within the given population, as evidenced by EGFP 
fluorescence, was scored as either predominantly nuclear, pancellular, or 
predominantly cytoplasmic. The results of seven independent experiments were 
averaged and compared, seen graphically in Figure 11 and as raw data in Table 
2. Data from this quantitative analysis supports the conclusions drawn from the 
qualitative analysis. Consistent with what was seen in the qualitative assay 
91.8% +/- 3% of EGFP-16E7 wild type and 92.3% +/- 2.6% of EGFP-16E7R66A 
expressing cells exhibited a predominantly nuclear phenotype compared to only 
14% +/- 4.8% of EGFP-16E7LRLCV65AAAAA expressing cells. Conversely, 84.8% +/- 
4.2% of EGFP-16E7LRLCV65AAAAA expressing cells exhibited a pancellular 
phenotype compared to 8% +/- 3.1% and 7.7% +/- 2.6% of cells expressing 
either EGFP-16E7 wild type or EGFP-16E7R66A, respectively. Together these 
data support the conclusions drawn from the qualitative assay in that these 
hydrophobic residues of HPV16 E7 are responsible, at least in part, for the 
nuclear localization of EGFP-16E7 whereas the positively charged arginine 
residue plays no role in the function of the cNLS. 
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Figure 11: Mutation of Hydrophobic Residues within the Zinc Binding 
Domain of EGFP-16E7 Alters the Localization in Transiently Transfected 
HeLa Cells 
The data from seven experiments using EGFP-16E7 wild type, EGFP-16E7LRLCV65AAAAA, EGFP-
16E7R66A, and EGFP plasmids have been used for the quantification graphic representation of the 
phenotypic distribution of transfected HeLa cells. Blue bars represent cells exhibiting predominant 
nuclear localization; red bars represent cells exhibiting pancellular localization; green bars 
represent cells exhibiting predominant cytoplasmic localization. 
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Similar to what was observed in the previous section when examining the role of 
the zinc-binding domain in mediating cNLS function, the pancellular phenotype 
observed in cells expressing EGFP-16E7LRLCV65AAAAA suggests that EGFP-16E7 
is able to enter the nucleus in the absence of this particular patch of hydrophobic 
amino acid residues. As before, it was unclear as to if the ability of EGFP-16E7 
to enter the nucleus in this context is a result of passive diffusion across the NPC, 
or if the function of the cNLS is only partially dependent upon these hydrophobic 
residues. To eliminate the possibility of passive diffusion across the NPC both 
2xEGFP-16E7LRLCV65AAAAA and 2xEGFP-16E7R66A mutants, as well as 2xEGFP-
16E7 wild type and 2xEGFP, were transiently transfected into HeLa cells and 
their resultant sub-cellular localizations were examined via confocal fluorescence 
microscopy (Figure 12). Similar to what was observed for their EGFP-16E7 
counterparts, both 2xEGFP-16E7 wild type (panels 12A, 12E and 12I) and 
2xEGFP-16E7R66A (panels 12B, 12F, and 12J) expressing cells exhibited a 
predominantly nuclear phenotype. However, cells expressing 2xEGFP-
16E7LRLCV65AAAAA (panels 12C, 12G, and 12K) exhibited a predominantly 
cytoplasmic phenotype. These data suggest that the pancellular phenotype 
observed in cells expressing EGFP-16E7LRLCV65AAAAA was likely the result of 
passive diffusion across the NPC and that these hydrophobic residues are, in 
fact, essential for the function of the cNLS of HPV16 E7.  
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Figure 12: Mutation of Hydrophobic Residues within the Zinc Binding 
Domain of 2xEGFP-16E7 Alters the Localization in Transiently Transfected 
HeLa Cells 
HeLa cells were transfected with either 2xEGFP-16E7 wild type (panels A, E, I), 2xEGFP-
16E7LRLCV65AAAAA (panels B, F, J), 2xEGFP-16E7R66A (panels C, G, K), or 2xEGFP (panels D, H, 
L) plasmids and examined by confocal fluorescence microscopy at 24 h post transfection. Panels 
A-D represent DAPI staining of the nuclei, panels E-H represent EGFP fluorescence, and panels 
I-L represent the merge of EGFP and DAPI fluorescence. 
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Identical to what was done for the EGFP-16E7LRLCV65AAAAA or EGFP-16E7R66A 
mutants, a quantitative analysis of the phenotypic distribution of the 2xEGFP-
16E7LRLCV65AAAAA or 2xEGFP-16E7R66A transiently transfected HeLa cell 
populations was performed in addition to the qualitative analysis. HeLa cells 
transiently transfected with either 2xEGFP-16E7 wild type, 2xEGFP, 2xEGFP-
16E7LRLCV65AAAAA or 2xEGFP-16E7R66A were examined via confocal fluorescence 
microscopy and every positively transfected cell within the given population, as 
evidenced by EGFP fluorescence, was scored as either predominantly nuclear, 
pancellular, or predominantly cytoplasmic. The results of seven independent 
experiments were averaged and compared, seen graphically in Figure 13 and as 
raw data in Table 2. Similar to what was observed in the context of EGFP-16E7, 
these data support the conclusions drawn from the qualitative assay. Like their 
EGFP-16E7 counterparts, the majority of both 2xEGFP-16E7 wild type and 
2xEGFP-16E7R66A expressing cells exhibit a predominantly nuclear phenotype 
(77.8%+/- 6.8% and 86.2% +/- 4.2%, respectively) with the majority of the 
remaining cells exhibiting a pancellular phenotype (19.7% +/- 3.8% and 12.1% 
+/- 3.4%, respectively). Significantly, the majority 2xEGFP-16E7LRLCV65AAAAA 
expressing cells exhibit a predominantly cytoplasmic phenotype (84.9% +/- 4.3%) 
with the majority of the remaining cells exhibiting a pancellular phenotype (14.6% 
+/- 4.2%). Together these data further support the conclusion that these 
hydrophobic residues, 65LRLCV69, are responsible for the nuclear localization of 
EGFP-16E7 whereas the positively charged arginine 66 residue plays no 
significant role in the function of the cNLS. 
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Figure 13: Mutation of Hydrophobic Residues within the Zinc Binding 
Domain of 2xEGFP-16E7 Alters the Localization in Transiently Transfected 
HeLa Cells 
The data from seven experiments using 2xEGFP-16E7 wild type, 2xEGFP-16E7LRLCV65AAAAA, 
2xEGFP-16E7R66A, and 2xEGFP plasmids have been used for the quantification graphic 
representation of the phenotypic distribution of transfected HeLa cells. Blue bars represent cells 
exhibiting predominant nuclear localization; red bars represent cells exhibiting pancellular 
localization; green bars represent cells exhibiting predominant cytoplasmic localization. 
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n=7 Mostly Nuclear Pancellular Mostly Cytoplasmic 
EGFP-16E7 1568 152 2 
EGFP-16E7 LRLCV65AAAAA 245 1573 23 
EGFP-16E7 R66A 830 133 11 
EGFP 25 1193 3 
2xEGFP-16E7 1658 412 30 
2xEGFP-16E7 LRLCV65AAAAA 12 365 2002 
2xEGFP-16E7 R66A 867 109 11 
2xEGFP 4 204 1632 
 
 
Table 2: Quantitative Analysis of the Intracellular Localizations of 
Hydrophobic Residue and R66A Mutants 
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To ensure that the results observed were not due to degradation of any of the 
EGFP-16E7 or 2xEGFP-16E7 proteins, immunoblot analysis with an anti-EGFP 
antibody of all the EGFP-16E7 and 2xEGFP-16E7 wild type, hydrophobic residue, 
and R66A mutant proteins was performed (Figure 14). These data indicate that 
all wild type, hydrophobic residue, and R66A mutant EGFP-16E7 proteins are 
intact and expressed at the correct molecular weight; however, both the wild type 
and mutant 2xEGFP-16E7 proteins exhibit evidence of some proteolytic 
degradation. 
 
While these data support the observations and conclusions drawn from the 
previous experiments, that the patch of hydrophobic residues, 65LRLCV69, within 
the zinc-binding domain of HPV16 E7 are essential for cNLS function and that 
the charged arginine residue at position 66 has no significant role in the function 
of the cNLS, they suggest that some of the shift in localization observed for the 
2xEGFP-16E7 mutants may have been due to degradation rather than solely due 
as a result of hydrophobic residue substitution.  
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Figure 14: EGFP-16E7 and 2xEGFP-16E7 Hydrophobic Residue and R66A 
Mutants are Properly Expressed in HeLa Cells 
HeLa cells were transfected with, 2xEGFP-16E7 (lane 1), 2xEGFP-16E7LRLCV65AAAAA (lane 2), 
2xEGFP-16E7R66A (lane 3), 2xEGFP (lane 4), EGFP-16E7 (lane 5), EGFP-16E7LRLCV65AAAAA (lane 
6), EGFP-16E7R66A (lane 7), or EGFP (lane 8) plasmids. Cell lysates were prepared 24 h post 
transfection and probed with an EGFP antibody.  
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To further confirm the conclusions drawn from the previous in vivo transient 
transfection experiments, in vitro nuclear import assays were performed using 
the previously generated hydrophobic residue and arginine 66 mutants in the 
context of GST-16cE7 according to previously established protocols (1, 2, 26, 27, 
33, 51-53, 60). In these experiments, digitonin permeablized HeLa cells were 
incubated with either, GST-M9 as a positive control, GST-16cE7, GST-
16cE7LRLCV65AAAAA, GST-16cE7R66A, or GST as a negative control, in the 
presence of either transport buffer or HeLa cytosol. Detection of the GST fusion 
proteins was via specific antibodies and immunofluorescence staining and 
subsequent examination by confocal fluorescence microscopy, the results of 
which can be seen in Figure 15. These data show that, like GST-M9 (panels 15A 
and 15F), GST-16cE7 (panels 15B and 15G) is imported into the nucleus in the 
presence of HeLa cytosol, as expected. In addition these data show that, similar 
to what previously observed in the transient transfection assays, whereas 
mutation of the arginine residue in GST-16cE7R66A (panels 15D and 15I) did not 
affect its ability to import into the nucleus in the presence of HeLa cytosol, 
mutation of the hydrophobic residues in GST-16cE7LRLCV65AAAAA (panels 15C and 
15H) resulted in a loss of nuclear import activity in the presence of HeLa cytosol. 
As expected, no nuclear import was observed for GST itself (panels 15E and 
15J). Together these data support the previous conclusion that the patch of 
hydrophobic residues, 65LRLCV69, within the zinc-binding domain of HPV16 E7 is 
essential for cNLS function and that the charged arginine residue at position 66 
has no significant role in the function of the cNLS. 
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Figure 15: Mutation of Hydrophobic Residues within the Zinc Binding 
Domain of GST-16cE7 Alters the Localization in Nuclear Import Assays 
Digitonin-permeabilized HeLa cells were incubated with either GST-M9 (panels A and F), GST-
16cE7 (panels B and G), GST-16cE7LRLCV65AAAAA (panels C and H), GST-16cE7R66A (panels D and 
I), or GST (panels E and J) in the presence of transport buffer (panels A-E) or HeLa cytosol and 
energy mix (panels F-J). 
 
 
 
 
 
	   69	  
As a control to confirm the results observed in the previous in vitro nuclear import 
assay were not due to protein degradation, a sample of each of the purified GST 
fusion proteins used was denatured with SDS and beta mercaptoethanol, boiled, 
then electrophoretically separated on a 12% polyacrylamide gel. Proteins were 
then visualized via Coomassie Blue staining (Figure 16). Results indicate that 
GST-16cE7 (lane 3), GST-16cE7LRLCV65AAAAA (lane 4), and GST-16cE7R66A (lane 
5), as well as the positive GST-M9 (lane 2), and negative GST (lane 1) control 
were all properly expressed and purified for use in the nuclear import assays. 
These data indicate that the results observed in the previous nuclear import 
assay were legitimate and not due improper protein expression or degradation. 
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Figure 16: GST-16cE7 Hydrophobic Residue and R66A Mutants are 
Properly Expressed and Purified for use in Nuclear Import Assays 
Proteins expressed in BL21-CondonPlus cells, GST (lane 1), GST-M9 (lane 2), GST-16cE7 (lane 
3), GST-16cE7LRLCV65AAAAA (lane 4), and GST-16cE7R66A (lane 5), were purified and run on a 12% 
SDS-PAGE gel. Proteins were visualized by staining with Coomassie blue. 
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HPV16 E7 Interacts with the FG-Nucleoporin Nup62 
 
As previously discussed, the mechanism by which hydrophobic residue patches, 
including that of HPV11 E7, mediate nuclear import is through non-specific 
hydrophobic interactions with the FG repeats in nucleoporins (38, 50). To 
examine the possibility that the hydrophobic patch of HPV16 E7, 65LRLCV69, 
affected nuclear import through direct non-specific interactions with FG-Nups 
isolation assays were performed. For these experiments we used the FG-
Nupleoporin Nup62, located at the central transport channel of the NPC, which 
has previously been shown to interact with karyopherins (66). In these 
experiments either GST-Nup62N, containing the FG domain of Nup62, or GST, 
as a negative control, was immobilized on glutathione-Sepharose beads and 
incubated with the cell lysates of HeLa cells expressing EGFP-16E7 wild type, 
EGFP-16E7LRLCV65AAAAA, EGFP-16E7R66A, or EGFP. Bound proteins were then 
eluted and analyzed via immunoblotting with an EGFP antibody, the results of 
which can be seen in Figure 17. Results show that both EGFP-16E7 wild type 
(lane 6) and EGFP-16E7R66A (lane 8) directly interacted with GST-Nup62N, but 
not GST (lanes 11 and 13, respectively). This is consistent with the previously 
observed nuclear localization. Critically, the hydrophobic residue mutant 
previously shown to prevent nuclear localization also inhibited the interaction of 
EGFP-16E7LRLCV65AAAAA with GST-Nup62N (lane 7), and likewise did not interact 
with GST (lane 12). The positive control, Kap β2 bound to GST-Nup62N (lane 
10) but not to GST itself (lane 15), whereas the negative control EGFP did not 
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bind to either one  (lanes 9 and 14). In addition, experiments assessing the 
binding of EGFP-16E7 wild type, EGFP-16E7LRLCV65AAAAA, EGFP-16E7R66A, or 
EGFP to GST-Nup62C, which lacks the FG domain of Nup62, demonstrated 
none of the EGFP fusion proteins are able to bind in the absence of the FG 
domain (data not shown).Taken all together, these data strongly suggest that the 
patch of hydrophobic residues, 65LRLCV69, within the zinc-binding domain of 
HPV16 E7 is essential for cNLS function through a direct interaction with the FG 
repeats in nucleoporins, and furthermore that the charged arginine residue at 
position 66 has no significant role in the function of the cNLS or the interaction 
with FG-Nups. 
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Figure 17: Mutation of the Hydrophobic Residues within the Zinc Binding 
Domain of EGFP-16E7 Disrupt the Interaction with GST-Nup62N in Isolation 
Assays 
HeLa cells were transfected with EGFP-16E7, EGFP-16E7LRLCV65AAAAA, EGFP-16E7R66A, and 
EGFP plasmids. Cell lysates were prepared 24 h  post transfection and probed with either EGFP 
antibody (lanes 1-4) or Kap β2 antibody (lane 5). GST-Nup62N (lanes 6-10) and GST (lanes 11-
15) immobilized on glutathione-Sepharose were incubated with the cell lysates and the bound 
proteins were eluted and analyzed via immunoblotting with an EGFP antibody (lanes 6-9, and 11-
14). Binding of Kap β2 to GST-Nup62N and GST was analyzed as a control (lanes 10 and 15). 
	   74	  
HPV16 E7 Directly Interacts with the Nuclear Export Receptor CRM1 
 
Previous work in the Moroianu lab examining the nucleocytoplasmic transport of 
HPV16 E7 revealed 2 putative, overlapping C-terminal leucine-rich NES 
(76IRTLEDLLM84 and 79LEDLLMGTLGI89) (28). Further analysis of the NES 
identified 76IRTLEDLLM84 as the major NES with the downstream LGI sequence 
enhancing the activity of the main NES (28). The identification of this leucine-rich 
NES mediating the nuclear export of HPV16 E7 suggests CRM1 may be its 
nuclear export receptor. To examine this possibility in vivo isolation assays were 
performed. In these experiments either GST-CRM1, or GST as a negative control, 
was immobilized on glutathione-Sepharose beads and incubated with the cell 
lysates of HeLa cells expressing EGFP-16cE7, EGFP-16cE7NESRev (as a 
positive control), or EGFP (as a negative control). Bound proteins were then 
eluted and analyzed via immunoblotting with an EGFP antibody (Figure 18). As 
expected, EGFP-16E7NESRev (lane 5) directly interacted with GST-CRM1, but 
not GST (lanes 8) and EGFP did not bind to either one (lanes 6 and 9). 
Interestingly, EGFP-16cE7 also bound GST-CRM1 and not to GST itself (lanes 4 
and 7, respectively). Together with the previous finding of Knapp et al., these 
data indicate that HPV16 E7 interacts with CRM1 nuclear export receptor via its 
leucine-rich C-terminal NES. 
 
 
 
	   75	  
 
 
 
 
 
 
Figure 18: EGFP-16cE7 Directly Interacts with GST-CRM1 in Isolation 
Assays 
HeLa cells were transfected with EGFP-16cE7, EGFP-16E7 NESRev, or EGFP and cell lysates 
were prepared 24 h post transfection and probed with an EGFP antibody (lanes 1-3). GST-CRM1 
(lanes 4-6) and GST (lanes 7-9) were immobilized on glutathione-Sepharose  and incubated with 
the cell lysates. The bound proteins were eluted and analyzed via immunobloting with an EGFP 
antibody. 
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Chapter 4 
Investigation of Serine 71 as a Putative Regulator of the Nucleocytoplasmic 
Trafficking of HPV16 E7 
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Substitution of Serine 71 to Alanine Does Not Affect the Nucleocytoplasmic 
Trafficking of HPV16 E7 in vivo 
 
As mentioned in the introduction, CKII phosphorylation within the CR2 domain 
has been shown to be important for the transformation ability of the HPV16 E7 
protein. Work has also shown that HPV16 E7 is differentially phosphorylated 
throughout the cell cycle, specifically that phosphorylation by CKII occurs 
primarily during G1, where phosphorylation of the serine 71 residue occurs 
primarily as the cell enters S phase (35). Additional studies have shown that 
HPV16 E7 has a functional NES mediating its nuclear export (20, 28). It was also 
recently demonstrated that CRM1 mediated NESs can be regulated by nearby 
phosphorylation events, and that regulated localization could be linked to the cell 
cycle (25). Together, these studies suggest the possibility that phosphorylation of 
serine 71 may play a role in regulating the HPV16 E7 NES, and that this may 
account for the observed effect on transformation potency and ability to 
successfully induce S phase. To examine this possibility site-directed 
mutagenesis was used to create several distinct serine 71 mutant constructs.  A 
hydrophobic substitution of the serine 71 residue to alanine in the context of 
EGFP-16E7 and EGFP-16cE7 was employed to create proteins mimicking non-
phosphorylated state, whereas a negatively charged substitution to both glutamic 
acid and aspartic acid in the context of EGFP-16cE7 and 2xEGFP-16cE7 created 
proteins mimicking the phosphorylated state (Figure 19).   
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Figure 19: Schematic Overview of Serine 71 Mutants 
 
 
 
 
 
 
 
	   79	  
After their generation, the EGFP fusion proteins mimicking the non-
phosphorylated state of the serine 71 residue, EGFP-16E7S71A and EGFP-
16cE7S71A, as well as EGFP-16E7 wild type, EGFP-16cE7, and the EGFP control 
were transiently transfected into HeLa cells and their resultant localizations were 
examined via confocal fluorescence microscopy (Figure 20). Qualitative 
examination of the localization of the hydrophobic serine 71 mutants 
demonstrated that EGFP-16E7S71A (panels 20D-F) exhibited no difference in 
localization compared to EGFP-16E7 (panels 20A-C) with both exhibiting a 
predominantly nuclear phenotype. Similarly, EGFP-16cE7S71A (panels 20J-L) 
exhibited no difference in localization compared to EGFP-16cE7 (panels 20G-I), 
both predominantly pancellular in their localization. As expected, EGFP (panels 
20M-O) localized pancellularly. These data suggest that phosphorylation of the 
serine 71 residue of HPV16 E7 is not necessary for its nucleocytoplasmic 
trafficking. 
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Figure 20: Substitution of Serine 71 to Alanine in EGFP-16E7 and EGFP-
16cE7 does not Alter the Localization in Transiently Transfected HeLa Cells 
HeLa cells were transfected with either EGFP-16E7 wild type (panels A-C), EGFP-16E7S71A 
(panels D-F), EGFP-16cE7 (panels G-I), EGFP-16cE7S71A (panels J-L), or EGFP (panels M-O) 
plasmids and examined by confocal fluorescence microscopy at 24 h post transfection. Panels B, 
E, H, K, and N represent the fluorescence of the EGFP and panels A, D, G, J, and M the DAPI 
staining of the nuclei. Panels C, F, I, L, and O represent a merge of EGFP and DAPI fluorescence. 
	   81	  
While the qualitative assessment of the localization of the hydrophobic serine 71 
mutants suggested phosphorylation of serine 71 was unnecessary for the 
nucleocytoplasmic trafficking of HPV16 E7, to ensure a more modest effect was 
not being overlooked, quantitative analysis of the phenotypic distribution of each 
of the transiently transfected HeLa cell populations in both the EGFP-16E7 and 
EGFP-16cE7 contexts was performed. In each case HeLa cells transiently 
transfected with either the EGFP-16E7 wild type, EGFP-16cE7 or the respective 
serine 71 mutants were examined via confocal fluorescence microscopy and 
every positively transfected cell within the given population, as evidenced by 
EGFP fluorescence, was scored as either predominantly nuclear, pancellular, or 
predominantly cytoplasmic. The results of three independent experiments were 
averaged and compared, seen graphically in Figure 21 and as raw data in Table 
3. These quantitative data serve to support the conclusions drawn from the 
previous qualitative assessment. These data show that 91.3% +/- 2.5% of the 
cells transfected with EGFP-16E7 exhibit a predominantly nuclear phenotype and 
8.3% +/- 2.1% exhibit a pancellular phenotype. Substitution of serine 71 to 
alanine in the context of EGFP-16E7 resulted in a similar phenotypic distribution 
where 84.3% +/- 4.2% of transfected cells exhibit predominantly nuclear 
localization and 15% +/- 3.5% exhibit pancellular localization. The majority of 
cells transfected with EGFP-16cE7 exhibited pancellular localization (89% +/- 
4.4%) with a small percentage (9.7% +/- 4.9%) exhibiting a predominantly 
nuclear localization phenotype. Similar to EGFP-16cE7 transfected cells, 95% +/- 
7% of cells transfected with EGFP-16cE7S71A exhibited pancellular localization 
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with 5% +/- 7% exhibiting a predominantly nuclear localization phenotype. 
Together these data support the conclusions drawn from the previous qualitative 
analysis and suggest that phosphorylation of the serine 71 residue is not 
necessary for the nucleocytoplasmic localization of HPV16 E7. 
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Figure 21: Substitution of Serine 71 to Alanine in EGFP-16E7 and EGFP-
16cE7 does not Alter the Localization in Transiently Transfected HeLa Cells 
The data from three experiments using EGFP-16E7 wild type, EGFP-16E7S71A, EGFP-16cE7, 
EGFP-16cE7S71A, or EGFP plasmids have been used for the quantification graphic representation 
of the phenotypic distribution of transfected HeLa cells. Blue bars represent cells exhibiting  
predominant nuclear localization; red bars represent cells exhibiting pancellular localization; 
yellow bars represent cells exhibiting predominant cytoplasmic localization. 
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n=3 Mostly Nuclear Pancellular Mostly Cytoplasmic 
EGFP-16E7 424 38 2 
EGFP-16E7 S71A 385 61 2 
EGFP-16cE7 53 436 6 
EGFP-16cE7 S71A 15 155 0 
EGFP 0 427 0 
 
 
Table 3: Quantitative Analysis of the Intracellular Localizations of Serine 71 
to Alanine Mutants 
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As a final control to ensure the qualitative and quantitative results observed were 
not due to degradation of any of the EGFP-16E7 or EGFP-16cE7 proteins, 
immunoblot analysis with an anti-EGFP antibody of EGFP-16E7, EGFP-16E7S71A, 
EGFP-16cE7, EGFP-16cE7S71A, and EGFP was performed (Figure 22). These 
data indicate that all EGFP-16E7 and EGFP-16cE7 proteins are intact and at the 
correct molecular weight. These data, together with both the qualitative and 
quantitative analyses, strongly suggest that the nucleocytoplasmic trafficking of 
HPV16 E7 is not dependent upon phosphorylation of the serine 71 residue. 
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Figure 22: EGFP-16E7 and EGFP-16cE7 Serine 71 to Alanine Mutants are 
Properly Expressed in HeLa Cells 
HeLa cells were transfected with EGFP-16E7 (lane 1), EGFP-16E7S71A (lane 2), EGFP-16cE7 
(lane 3), EGFP-16cE7S71A (lane 4), or EGFP (lane 5) plasmids. Cell lysates were prepared 24 h 
post transfection and probed with an EGFP antibody.  
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Substitution of Serine 71 to Negatively Charged Amino Acids Shifts the 
Localization Phenotype Distribution of HPV16 E7 in vivo 
 
While the serine 71 to alanine substitution experiments demonstrated that 
phosphorylation of the serine 71 residue is not necessary for nucleocytoplasmic 
trafficking, they did not indicate what effect, if any, the phosphorylation may have 
on the localization of HPV16 E7 within the cell. To examine the possibility, serine 
71 was substituted with an aspartic acid in the context of EGFP-16cE7 to mimic 
the phosphorylated state. HeLa cells were subsequently transiently transfected 
with EGFP-16cE7, EGFP-16cE7S71D, or EGFP and the resultant sub-cellular 
localizations were examined via confocal fluorescence microscopy (Figure 23). 
As expected, EGFP-16cE7 (panels 23A, 23D, and 23G) and EGFP (panels 23C, 
23F, and 23I) exhibited a pancellular phenotype. Qualitative examination of cells 
transiently transfected with EGFP-16cE7S71D (panels 23B, 23E, and 23H) 
demonstrated that the majority of cells exhibited a pancellular phenotype 
suggesting phosphorylation of the serine 71 residue may not affect 
nucleocytoplasmic trafficking of HPV16 E7. 
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Figure 23: Substitution of Serine 71 to Aspartic Acid in EGFP-16cE7 
Modestly Shifts the Phenotypic Distribution of Transfected HeLa Cells 
HeLa cells were transfected with either EGFP-16cE7 (panels A, D and G), EGFP-16cE7S71D 
(panels B, E and H), or EGFP (panels C, F, and I) plasmids and examined by confocal 
fluorescence microscopy at 24 h post transfection. Panels D-F represent the fluorescence of the 
EGFP and panels A-C the DAPI staining of the nuclei. Panels G-I represent a merge of EGFP 
and DAPI fluorescence. 
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While the previous results examining the localization of EGFP-16cE7S71D seem to 
indicate that phosphorylation of the serine 71 residue has no effect on the 
nucleocytoplasmic trafficking of HPV16 E7, it is possible that effects may be 
masked by passive diffusion across the NPC due to the low molecular weight of 
the EGFP-16cE7 construct. To eliminate this possibility, 2xEGFP-16cE7S71D, as 
well as 2xEGFP-16cE7 and 2xEGFP, were transiently transfected into HeLa cells 
and their resultant sub-cellular localizations were examined via confocal 
fluorescence microscopy (Figure 24). As expected, the majority of both 2xEGFP-
16cE7 (panels 24A, 24D, and 24G) and 2xEGFP (panels 24C, 24F, and 24I) 
exhibited a predominantly cytoplasmic phenotype. Interestingly however, while 
the majority of cells expressing 2xEGFP-16cE7S71D (panels 24B, 24E, 24H) 
exhibited a predominantly cytoplasmic phenotype, the phenotypic distribution of 
the resultant cell population was noticeably heterogeneous. While qualitative 
assessment of these data seems to indicate that phosphorylation of the serine 71 
residue does not affect nucleocytoplasmic trafficking of HPV16 E7, the 
heterogeneity of the 2xEGFP-16cE7S71D suggests the possibility that the effect of 
phosphorylation of the serine 71 residue may be modest and suggest the need to 
perform a more quantitative analysis. 
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Figure 24: Substitution of Serine 71 to Aspartic Acid in 2xEGFP-16cE7 
Modestly Shifts the Phenotypic Distribution of Transfected HeLa Cells 
HeLa cells were transfected with either 2xEGFP-16cE7 (panels A, D and G), 2xEGFP-16cE7S71D 
(panels B, E and H), or 2xEGFP (panels C, F, and I) plasmids and examined by confocal 
fluorescence microscopy at 24 h post transfection. Panels D-F represent the fluorescence of the 
EGFP and panels A-C the DAPI staining of the nuclei. Panels G-I represent a merge of EGFP 
and DAPI fluorescence. 
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Prior to performing quantitative analysis, additional qualitative analyses were 
performed substituting serine 71 with glutamic acid in lieu of aspartic acid.  HeLa 
cells were transiently transfected with, EGFP-16cE7S71E, EGFP-16cE7, or EGFP 
and the resultant sub-cellular localizations of the EGFP fusion proteins were 
examined via confocal fluorescence microscopy (Figure 25). Similar to what was 
observed in the previous series of experiments, both EGFP-16cE7 (panels 25A, 
25E, and 25I) and EGFP (panels 25D, 25H, and 25L) expressing cells exhibited 
a pancellular phenotype. Likewise, the majority of cells expressing EGFP-
16cE7S71E also exhibited a pancellular phenotype (panels 25C, 25G, 25K), 
however a substantial number exhibited a predominantly nuclear phenotype 
instead (panels 25B, 25F, and 25J). While these qualitative data are in 
agreement with the data obtained from the serine 71 to aspartic acid substitution 
experiments and suggest phosphorylation of serine 71 has no effect of the 
nucleocytoplasmic trafficking of HPV16 E7, the presence of a significant minority 
phenotype of EGFP-16cE7S71E expressing cells suggest there may be a modest 
effect not immediately obvious via qualitative analysis; thus further indicates the 
need to perform quantitative analysis. 
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Figure 25: Substitution of Serine 71 to Glutamic Acid in EGFP-16cE7 
Modestly Shifts the Phenotypic Distribution of Transfected HeLa Cells 
HeLa cells were transfected with either EGFP-16cE7 (panels A, E and I), EGFP-16cE7S71E 
(panels B, C, F, G, J and K), or EGFP (panels D, H, and L) plasmids and examined by confocal 
fluorescence microscopy at 24 h post transfection. Panels E-H represent the fluorescence of the 
EGFP and panels A-D the DAPI staining of the nuclei. Panels I-L represent a merge of EGFP and 
DAPI fluorescence. 
 
	   93	  
As with the serine 71 to aspartic acid mutant, the possibility exists that diffusion 
of EGFP-16cE7S71E across the NPC may be masking any effects of 
phosphorylation of the serine 71 residue on the nucleocytoplasmic trafficking of 
HPV16 E7. As a final qualitative assessment prior to performing quantitative 
analyses on the acidic serine 71 mutants, 2xEGFP-16cE7S71E, as well as 
2xEGFP-16cE7 and 2xEGFP, were transiently transfected into HeLa cells and 
their resultant sub-cellular localizations were examined via confocal fluorescence 
microscopy (Figure 26). As seen previously, the majority of 2xEGFP-16cE7 
(panels 26A, 26F, and 26K) and 2xEGFP (panels 26E, 26J, and 26O) expressing 
cells had a predominantly cytoplasmic phenotype. Cells expressing 2xEGFP-
16cE7S71E however were considerably more heterogeneous in their phenotypic 
distribution. While the majority of 2xEGFP-16cE7S71E expressing cells were still 
phenotypically predominantly cytoplasmic, a substantial number had a 
pancellular phenotype, and a small number a predominantly nuclear phenotype. 
Contrary to the initial conclusions that were drawn from these acidic serine 71 
substitution experiments, these more readily apparent data concerning the 
phenotypic heterogeneity of these 2xEGFP-16cE7S71E expressing cells further 
supports the possibility that phosphorylation of the serine 71 residue may 
modestly affect the nucleocytoplasmic trafficking of HPV16 E7. 
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Figure 26: Substitution of Serine 71 to Glutamic Acid in 2xEGFP-16cE7 
Modestly Shifts the Phenotypic Distribution of Transfected HeLa Cells 
HeLa cells were transfected with either 2xEGFP-16cE7 (panels A, F and K), 2xEGFP-16cE7S71E 
(panels BB-D, G-I, and L-N), or EGFP (panels E, J, and O) plasmids and examined by confocal 
fluorescence microscopy at 24 h post transfection. Panels F-J represent the fluorescence of the 
EGFP and panels A-E the DAPI staining of the nuclei. Panels K-O represent a merge of EGFP 
and DAPI fluorescence. 
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While the qualitative assessment of the localization of the acidic serine 71 
mutants initially suggested phosphorylation of serine 71 had no effect on the 
nucleocytoplasmic trafficking of HPV16 E7, the heterogeneous phenotypic 
distribution of each of the transiently transfected HeLa cell populations in both 
the 2xEGFP-16cE7S71D and 2xEGFP-16cE7S71E experiments suggested there 
may be a modest effect not immediately obvious via qualitative analysis. In order 
to assess this possibility quantitative analysis was performed. In each case HeLa 
cells transiently transfected with either the EGFP-16cE7, 2xEGFP-16cE7 or the 
respective acidic serine 71 mutants were examined via confocal fluorescence 
microscopy and every positively transfected cell within the given population, as 
evidenced by EGFP fluorescence, was scored as either predominantly nuclear, 
pancellular, or predominantly cytoplasmic. The results of seven independent 
experiments were averaged and compared, seen graphically in Figure 27 and as 
raw data in Table 4. These data show that while a small percentage of EGFP-
16cE7 expressing cells exhibit a predominantly nuclear phenotype (12.1%+/-
7.5% compared to 85.9% +/- 8% pancellular), both EGFP-16cE7S71D and EGFP-
16cE7S71E have a larger percentage of cells exhibiting a predominantly nuclear 
phenotype compared to pancellular cells (23.3% +/- 4.2% and 27.5% +/- 7.2% 
compared to 76% +/-4.6% and 72.4% +/- 7%, respectively). In the context of 
2xEGFP-16cE7 these modest differences are even more pronounced. The 
majority of 2xEGFP-16cE7 expressing cells (76.7% +/- 4.7%) are predominantly 
cytoplasmic with the majority of the remainder (21.4% +/- 4.4%) exhibiting a 
pancellular phenotype. Cells expressing 2xEGFP-16cE7S71D conversely are 
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much more evenly distributed with 57% +/- 2.8% exhibiting a predominantly 
cytoplasmic localization and 42.8% +/- 2.7% exhibiting a pancellular phenotype. 
Cells expressing 2xEGFP-16cE7S71E are even more phenotypically 
heterogeneous, with 54% +/- 16.8% exhibiting a predominantly cytoplasmic 
phenotype, 37.8% +/- 13.7% a pancellular phenotype, and 8.2% +/- 6.1% a 
predominantly nuclear phenotype.  
 
While these modest differences in localization observed between EGFP-16cE7, 
2xEGFP-16cE7 and their respective mutants suggest phosphorylation of the 
serine 71 residue may modestly affect the nucleocytoplasmic trafficking of 
HPV16 E7, statistical analysis using a two-tailed Student’s-T Test was performed 
to assess the significance of these data. While no statistical difference was 
observed between the predominantly nuclear or predominant cytoplasmic 
populations of EGFP-16cE7 and either EGFP-16cE7S71D or EGFP-16cE7S71E, a 
statistically significant difference was observed between their respective 
pancellular populations (p=0.035 and p=0.014 for EGFP-16cE7S71D and EGFP-
16cE7S71E, respectively). In addition, statistically significant differences were 
observed between all populations of 2xEGFP-16cE7 and both 2xEGFP-
16cE7S71D and 2xEGFP-16cE7S71E. Analysis between the pancellular and 
cytoplasmic populations of 2xEGFP-16cE7 and 2xEGFP-16cE7S71D 
demonstrated a high level of significance at p=1.18x10-5 and p=6.45x10-5, 
respectively. Similar results were observed between all populations of 2xEGFP-
16cE7 and 2xEGFP-16cE7S71E. Analysis between the nuclear populations 
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demonstrated significance at p=0.006, while difference between the pancellular 
and cytoplasmic populations showed a high level of significance at p=0.004 and 
p=0.001, respectively. Together these data further support that, contrary to what 
the qualitative data originally suggested, phosphorylation of the serine 71 residue 
modestly affects the nucleocytoplasmic trafficking of HPV16 E7. 
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Figure 27: Substitution of Serine 71 in EGFP-16E7 and 2xEGFP-16E7 to a 
Negatively Charged Residue Modestly Shifts the Phenotypic Distribution of 
Transfected HeLa Cells 
The data from seven experiments using EGFP-16cE7, EGFP-16cE7S71D, EGFP-16cE7S71E, EGFP, 
2xEGFP-16cE7, 2xEGFP-16cE7S71D, 2xEGFP-16cE7S71E, or 2xEGFP plasmids have been used 
for the quantification graphic representation of the phenotypic distribution of transfected HeLa 
cells. A statistical difference between the pancellular localization of EGFP-16cE7 and EGFP-
16cE7S71D was observed at p=0.035, between EGFP-16cE7 and EGFP-16cE7S71E at p=0.014, 
between 2xEGFP-16cE7 and 2xEGFP-16cE7S71D at p=1.18x10-5, and between 2xEGFP-16cE7 
and 2xEGFP-16cE7S71E at p=0.004. A statistical difference between the cytoplasmic localization 
of 2xEGFP-16cE7 and 2xEGFP-16cE7S71D was observed at p=6.45x10-5 and between 2xEGFP-
16cE7 and 2xEGFP-16cE7S71E at p=0.001. A statistical difference between the nuclear 
localization of 2xEGFP-16cE7 and 2xEGFP-16cE7S71E was observed at p=0.006. Blue bars 
represent cells exhibiting predominant nuclear localization; red bars represent cells exhibiting 
pancellular localization; yellow bars represent cells exhibiting predominant cytoplasmic 
localization. 
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n=7 Mostly Nuclear Pancellular Mostly Cytoplasmic 
EGFP-16cE7 300 2329 36 
EGFP-16cE7 S71D 600 1938 10 
EGFP-16cE7 S71E 565 1559 2 
EGFP 66 1759 26 
2xEGFP-16cE7 46 500 1820 
2xEGFP-16cE7 S71D 5 1235 1657 
2xEGFP-16cE7 S71E 152 668 790 
2xEGFP 0 10 393 
 
 
Table 4: Quantitative Analysis of the Intracellular Localizations of 
Negatively Charged Serine 71 Mutants 
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As a final control to ensure the qualitative and quantitative results observed were 
not due to degradation of any of the EGFP-16cE7 or 2xEGFP-16cE7 proteins, 
immunoblot analysis with an anti-EGFP antibody of EGFP-16cE7, EGFP-
16E7S71D, EGFP-16E7S71E, 2xEGFP-16cE7, 2xEGFP-16cE7S71D, EGFP-16E7S71E, 
and 2xEGFP was performed (Figure 28). These data indicate that all EGFP-
16cE7 and 2xEGFP-16cE7 proteins are intact and at the correct molecular 
weight.  
 
 
In total, these data suggest that mimicking phosphorylation of serine 71 can shift 
the distribution of localization phenotypes in HeLa cells, indicating that 
phosphorylation of the serine 71 residue may modestly affect the 
nucleocytoplasmic trafficking of the HPV16 E7 oncoprotein. 
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Figure 28: EGFP-16cE7 and 2xEGFP-16cE7 Acidic Serine 71 Mutants are 
Properly Expressed in HeLa Cells 
HeLa cells were transfected with EGFP-16cE7 (lane 1), EGFP-16cE7S71D (lane 2), EGFP-
16cE7S71E (lane 3), EGFP (lane 4), 2xEGFP-16cE7 (lane 5), 2xEGFP-16cE7S71D (lane 6), 
2xEGFP-16cE7S71E (lane 7), or 2xEGFP (lane 8) plasmids. Cell lysates were prepared 24 h post 
transfection and probed with an EGFP antibody.  
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Chapter 5 
Discussion 
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The human papillomaviruses (HPVs) are small, non-enveloped, double-stranded 
DNA tumor viruses with a 55-nm icosahedral capsid, and genomes typically 
containing about 8,000 base pairs. Infection is highly tissue specific, with all of 
the HPVs exhibiting a marked tropism for squamous basal epithelial cells. The 
largest individual group of the more than 200 described HPVs are the Alpha 
papillomaviruses which consist of both cutaneous viruses known to cause 
common warts, as well as the approximately 40 types known to infect mucosal 
epithelium. These Alpha HPVs may be sub-divided into high and low-risk groups, 
dependent upon the frequency with which they have been linked to the malignant 
progression of their resultant lesions. Most of the HPVs that infect the squamous 
epithelium of the genital tract can be classified as low risk, about 90% of which 
are caused specifically by HPV6 and HPV11, and only very rarely lead to 
cancers even if left untreated. Conversely, 15 of the sexual transmitted genital 
HPVs can be classified as high risk, notably HPV16, which may result in 
squamous intraepithelial lesions capable of progressing to invasive carcinomas 
(12, 13). This capacity to progress from intraepithelial lesions to invasive 
carcinomas is largely the result of two HPV oncogenes, E6 and E7, which have 
been found to be consistently expressed in the tumors of virtually all HPV 
associated carcinomas. Together, E6 and E7 work cooperatively to induce 
cellular immortalization and transformation, E7 primarily promoting the formation 
of benign tumors, and E6 responsible for progression of the tumors to 
malignancy.  
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While the E6 protein has been shown to affect its functions largely through the 
formation of a trimeric complex with p53 and E6AP, the E7 protein affects its 
biological activities through the association and subversion of a number of 
cellular regulatory complexes involved in several key host cell signal transduction 
networks. The best characterized interaction of E7 is with the retinoblastoma 
protein (pRB) and related pocket proteins p107 and p130 which, along with 
critical interactions with other nuclear proteins, will induce hyperproliferation via 
deregulation of G1/S phase entry and allow the virus access to the host cell 
replication machinery in normally quiescent cells that otherwise could not support 
viral replication. In addition to these described nuclear activities, E7 has also 
been shown to bind cytoplasmic proteins, notably with the microtubule-
associated N-end ubiquitin ligase p600 that is thought to prevent anoikis in 
response to deregulated S-phase entry, as well as to the nuclear mitotic 
apparatus protein suggesting critical roles for E7 in both the nucleus and in the 
cytoplasm. 
 
The research we have performed in this study has focused on further 
investigation of the mechanism and regulation of the nucleocytoplasmic 
trafficking of high risk HPV16 E7 oncoprotein. Previous study by Angeline et al. 
revealed that while in vitro nuclear import of HPV16 E7 was dependent on the 
cytosolic factor Ran, it was independent of either importin β or transportin (2). In 
vitro nuclear import assays showed that HPV16 E7 import was independent of its 
ability to bind pRB. In addition, in vitro isolation assays revealed that HPV16 E7 
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does not bind to Ran or its import receptor, p10/NTF2. Together, these data 
demonstrated that HPV16 E7 is not imported by ‘piggy-backing’ onto the import 
mechanisms of Ran and suggested HPV16 E7 entry into the nucleus occurs 
through a non-classical, Ran dependent pathway (2). Subsequent work by Knapp 
et al. confirmed in vivo that HPV16 E7 binding to pRB is not required for nuclear 
import and further showed that CKII phosphorylation, likewise, was not required 
for nuclear import (28). Further in vitro analysis showed a sub-region of the CR3 
domain (aa 44-98) that contained the zinc-finger of HPV16 E7 was sufficient to 
mediate nuclear import of a GST reporter in the presence of only exogenous 
RanGDP (28).  
 
In this study we have further investigated the described cNLS within the CR3 
domain of HPV16 E7 using both transfection assays in HeLa cells with EGFP 
fusions containing 16E7 and nuclear import assays in digitonin-permeabilized 
cells with GST fusions to the C-terminal domain of 16E7. As previously 
mentioned, the CR3 domain containing the cNLS contains a unique zinc-binding 
domain consisting of two Cys-X-X-Cys motifs separated by 29 amino acids that is 
conserved between the high and low risk HPV types (31). In addition, the 
integrity of this zinc-binding domain has previously been shown to be necessary 
for both dimerization and, in high risk HPV types, the transformative capacity of 
E7 (9, 37). Here we have presented data that mutations of Cys residues in the 
two Cys-X-X-Cys motifs that affect the zinc binding clearly disrupt the nuclear 
import of the resultant EGFP-16E7 and 2xEGFP-16E7 mutants. These data 
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strongly suggest that, in addition to capacity for dimerization and transformation 
potential, the integrity of the zinc-binding domain of HPV16 E7 is critical for the 
nuclear import activity of the cNLS. A previous report has shown that another 
viral protein with functions similar to that of both E6 and E7, the TAX protein of 
human T lymphotropic virus type 1 (HTLV-1), also enters the nucleus in a 
manner mediated by its zinc-binding domain (73). The cysteine residues involved 
in zinc conjugation within the CR3 domain of E7 proteins are the most highly 
conserved cysteine residues among the different HPV types and previous work 
by Piccioli et al. has described a similar mechanism of nuclear import mediated 
by the cNLS of low risk HPV11 E7 (60). Interestingly however, we observed 
different results from what was described for HPV11 E7 when we mutated the 
conserved cysteine 59 residue, not involved in zinc binding, in the context of 
either EGFP-16E7 or 2xEGFP-16E7. Piccioli et al. described a shift from 
predominantly nuclear localization to pancellular localization when the cysteine 
59 residue was changed to either an alanine or aspartic acid in the context of 
either low risk 11E7 or 11cE7. Here we present data that show mutation of the 
conserved cysteine 59 residue to alanine results in only a modest reduction in 
the proportion of cells exhibiting a predominantly nuclear phenotype with a 
corresponding increase in the fraction exhibiting either a pancellular phenotype in 
the context of EGFP-16E7, or pancellular and a very small number of 
predominantly cytoplasmic in the context of 2xEGFP-16E7. These data suggest 
that, while like HPV11 E7 this conserved cysteine 59 residue is involved, its role 
in the nuclear import of HPV16 E7 is less than in that of HPV11 E7. 
	  107	  
Further investigation into how the zinc binding domain of HPV16 E7 facilitates 
nuclear import suggests that one mechanism is via direct low affinity hydrophobic 
interactions between E7 and phenylalanine-glycine (FG) repeat rich nucleoporins 
in a manner similar to that employed by traditional nuclear import receptors. A 
previous study has demonstrated that surface hydrophobicity of the nuclear 
import receptors was sufficient to provide access to the nuclear pore complex 
(NPC) and furthermore that translocation involved non-specific interactions 
between small hydrophobic patches on the surface of the receptors and the FG 
repeats in the nucleoporins (50). In addition, the previously mentioned report on 
the HTLV-1 TAX protein, and more recent work by McKee et al. on HPV11 E7 
have demonstrated that the manner by which their respective zinc-binding 
domains mediate nuclear import is via direct interactions with FG-nucleoporins at 
the NPC (38, 73). McKee et al. additionally demonstrated that a small mostly 
hydrophobic patch within the zinc binding domain was essential for the 
interaction of HPV11 E7 with the FG domain of Nup62, a nucleoporin located in 
the midplane of the NPC and involved in nuclear import and export (38). 
Significantly, like HPV11 E7, the zinc-binding domain of HPV16 E7 is very rich in 
nonpolar hydrophobic residues, the majority of which are arranged in 
hydrophobic patches, suggesting a similar mechanism for how the zinc-binding 
domain of HPV16 E7 is able to mediate nuclear import. Here we have presented 
data from transfection assays that strongly support that, similar to HPV11 E7, 
HPV16 E7 interacts via its zinc-binding domain with the FG domain of Nup62 and 
that a mostly hydrophobic patch, 65LRLCV69, with significant homology to the 
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previously characterized patch in HPV11 E7 is critical for both this interaction, 
and for the nuclear localization of HPV16 E7. Mutation of the hydrophobic 
residues to alanine was sufficient to disrupt the predominantly nuclear 
localization in the context of EGFP-16E7 with the majority of cells expressing the 
mutant EGFP-16E7LRLCV65AAAAA exhibiting a pancellular phenotype. In the context 
of 2xEGFP-16E7, with a molecular weight beyond the passive diffusion limit 
across the NPC, mutation of the hydrophobic residues had a more pronounced 
effect as it was able to completely disrupt the nuclear localization with the 
majority of the 2xEGFP-16E7LRLCV65AAAAA expressing cells exhibiting 
predominantly cytoplasmic localization. In addition we have presented data from 
nuclear import assays that show that mutation of the hydrophobic residues to 
alanine completely disrupts nuclear import in the context of GST-16cE7. 
Interestingly, no change in localization was observed in either the transfection 
assays, or the nuclear import assays by mutating the arginine 66 residue to 
alanine, suggesting that the positively charged residue has no role in the nuclear 
import of HPV16 E7. In addition to examining nuclear localization, we have also 
presented data through the use of isolation assays demonstrating that HPV16 E7 
is capable of directly interacting with the FG domain of Nup62. Significantly, 
mutation of the hydrophobic residues to alanine inhibited the interaction of 
HPV16 E7 with the FG domain of Nup62, suggesting that the hydrophobic 
residues of this sequence play a critical role in facilitating the observed 
interaction of HPV16 E7 and Nup62. Overall we have presented data that 
strongly suggests that the cNLS mediated nuclear import of HPV16 E7 is via 
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hydrophobic interactions of the zinc-binding domain with the FG nucleoporin 
Nup62 at the NPC. It is likely that HPV16 E7 may interact with other FG 
nucleoporins at the NPC during its nuclear import. 
 
While the mechanism of nuclear import of high risk HPV16 E7 oncoprotein is 
conserved with that of HPV11 E7 protein (with preliminary data suggesting with 
E7 proteins of other HPV types as well), it is unique in comparison to the other 
HPV proteins like L1 and L2 capisd proteins and E6 oncoprotein that use 
different karyopherins to enter the nucleus (5, 26, 27, 29, 33, 51-53, 71, 78). 
Other viral and cellular proteins use this karyopherin independent nuclear import 
mediated by direct binding to FG-nucleoporins. As previously mentioned, another 
viral oncoprotein, the TAX protein of HTLV-1 also enters the nucleus via direct 
hydrophobic interactions of its zinc-binding domain with the FG-nucleoporin 
Nup62 at the NPC (73). A variety of cellular proteins such as PU.1 transcription 
factor, Smad3, MAPK, ERK2, and Stat1 have all been shown to enter the 
nucleus independent of karyopherins mediated by direct binding to FG-
nucleoporins (34, 36, 75-77). Yet while not unique, it remains unclear as to why 
the HPV E7 proteins alone of the HPV proteins make use of this mechanism in 
lieu of karyopherin mediated translocation across the NPC. We can only 
speculate at this time, but the relatively small size and richness in hydrophobic 
residues may place constraints upon the E7 proteins absent in other HPV 
proteins. For example, one possibility may be that the presence of a patch of 
basic residues characteristic of a classic NLS in the richly hydrophobic CR3 
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domain may disrupt the folding of the zinc-binding domain, dimerization, or one 
or more binding partner interactions associated with the CR3 domain of E7. 
Dimerization, for example has previously been shown to occur between 
hydrophobic regions within the CR3 domain; substitution of 65LRLCV69 with the 
basic residues of a classic monopartite NLS would likely disrupt the hydrophobic 
interactions between the β2 strand of one E7 with the β3 strand of a second and 
may prevent dimerization (31). A second possibility may be that, similar to what 
was described for Stat1, karyopherin independent nuclear import along with 
CRM1 dependent nuclear export may cooperate to maintain the appropriate 
subcellular localization of HPV E7 in a way that karyopherin mediated import 
could not (34). A third possibility may be that the use of karyopherin independent 
nuclear import may allow the HPV E7 protein, which exists in the cell in relatively 
low concentrations relative to other cellular proteins entering the nucleus, a 
mechanism of entry into the nucleus without having to compete for import 
receptors with other cellular cargos.  
 
While we have presented a variety of new data characterizing the mechanism of 
the cNLS, we still have not demonstrated what role the small GTPase Ran plays 
in mediating nuclear import of HPV16 E7. As previously mentioned, Angeline et 
al. had previously demonstrated that while nuclear import of HPV16 E7 was 
independent of karyopherins, import was dependent on the presence of Ran (2). 
At the time the possibility was suggested that Ran may by acting to stimulate the 
release of E7 from the FG-nucleoporins at the NPC and into the nucleus. The 
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data we have presented here further support this possibility and provide an 
avenue for biochemical testing. Using isolation assays we have shown the 
interaction between EGFP-16E7 and the FG domain of Nup62. The addition of 
recombinant Ran-GTP to elute the EGFP-16E7 from Nup62 could be used in the 
future to test this hypothesis.  
 
In addition to work characterizing the nuclear import of HPV16 E7, Knapp et al. 
also demonstrated that the CR3 domain, despite the presence of a cNLS, 
exhibited mostly cytoplasmic localization (28). Knapp et al. demonstrated that the 
addition of either the inhibitor Leptomycin B (LMB) or ratjadone (RJA) to transient 
transfection assays consistently changed the localization of the 16cE7 from 
predominantly cytoplasmic, to predominantly nuclear suggesting a weaker NLS 
and a stronger NES (28). Examination of the 16cE7 amino acid sequence 
revealed 2 putative, overlapping leucine-rich NES (76IRTLEDLLM84 and 
79LEDLLMGTLGI89) (28). Further analysis of the NES identified 76IRTLEDLLM84 
as the major NES with the downstream LGI sequence enhancing the activity of 
the main NES (28). More recent work in the Moroianu lab also characterized a 
leucine-rich NES in the C-terminal domain of low risk HPV11 E7 that has a high 
degree of homology to the NES of HPV16 E7 (38). It was also shown that the C-
terminal domain of HPV11 E7 containing the NES directly interacts with CRM1 
nuclear export receptor (38). In this study we have presented data from isolation 
assays demonstrating that, similar to what was observed for HPV11 E7, the CR3 
domain of HPV16 E7 directly interacts with CRM1. These data serve to provide 
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further biochemical support to the findings of Knapp et al. that the NES of HPV16 
E7 mediates its nuclear export in a CRM1-dependent manner.  
 
In addition to the previously described features, the CR3 domain has also been 
shown to have a high risk HPV conserved serine 71 residue capable of being 
phosphorylated (35, 41, 49). Phosphorylation of the HPV16 E7 oncoprotein has 
previously be shown to be critical for its function; phosphorylation of CKII within 
the CR2 domain, for example, has been shown to be important for the 
transformation ability of the HPV16 E7 protein. Additional work has also shown 
that HPV16 E7 is differentially phosphorylated throughout the cell cycle, 
specifically that phosphorylation by CKII occurs primarily during G1, where as 
phosphorylation of the serine 71 residue occurs primarily as the cell enters S 
phase (35).  While the activity of the CKII phosphorylation has been well 
described, neither the kinase, mechanism, nor the function has yet been 
described for phosphorylation of the serine 71 residue. One potential function 
that has been hypothesized is that phosphorylation of the serine 71 residue may 
provide a means of regulating E7 activity throughout the cell cycle (35, 41, 49). 
Interestingly, recent studies have demonstrated that CRM1 mediated NESs can 
be regulated by nearby phosphorylation events, and that regulated localization 
could be linked to the cell cycle (25). While speculative, the proximity of the 
serine 71 residue to the previously described NES of HPV16 E7 suggests the 
possibility that phosphorylation of serine 71 may play a role in regulating the 
HPV16 E7 NES, and that this may account for the observed effect on the 
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transformation potency and ability to successfully induce S phase. Here we have 
presented data from transfection assays that partially support this hypothesis. 
Mutation of the serine 71 residue to either aspartic or glutamic acid, mimicking 
the phosphorylated state, in both EGFP-16cE7 and 2xEGFP-16cE7 was able to 
modestly shift the distribution of localization phenotypes in HeLa cells toward 
more nuclear localization. Interestingly, mutation of the serine 71 to alanine in the 
context of EGFP-16E7 or EGFP-16cE7 resulted in no change in the distribution 
of localization phenotypes in HeLa cells. These data suggest that while 
phosphorylation of the serine 71 residue may modestly affect the 
nucleocytoplasmic trafficking of the HPV16 E7 oncoprotein by interfering with 
CRM1 mediated nuclear export, phosphorylation of serine 71 does not appear to 
occur in HeLa cells.  
 
While theses data we have presented demonstrate mimicking serine 71 
phosphorylation results in statistically significant change in the distribution of 
2xEGFP-16cE7 localization phenotypes in transfected HeLa cells, 
phosphorylation was not sufficient to completely abrogate the nuclear export and 
resulted in only a modest shift toward nuclear localization. While speculative, it is 
possible that, as serine 71 is phosphorylated only in S-phase, phosphorylation 
acts to shift the steady state localization of E7 in response to changing demands 
throughout the cell cycle. In the future it may be interesting to investigate this 
possibility by examining serine 71 phosphorylation mutants in HeLa cells 
arrested in S-phase with thymidine and comparing the resultant localizations to 
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cells arrested in other phases of the cell cycle. Likewise, comparison of the 
localization of wild-type EGFP-16E7, as well as the serine phosphorylation 
mutants, in primary keratinocytes arrested in S-phase to other phases of the cell 
cycle may provide further insight into this potential modulatory effect of serine 71 
phosphorylation on the nuclear export of HPV16 E7. 
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